Breast	breast	NN	O
cancer	cancer	NN	O
is	be	VBZ	O
the	the	DT	O
most	most	RBS	O
commonly	commonly	RB	O
diagnosed	diagnose	VBN	O
cancer	cancer	NN	O
among	among	IN	O
women	woman	NNS	O
worldwide	worldwide	RB	O
.	.	.	O

A	a	DT	O
majority	majority	NN	O
of	of	IN	O
patients	patient	NNS	O
diagnosed	diagnose	VBN	O
with	with	IN	O
breast	breast	NN	O
cancer	cancer	NN	O
go	go	VB	O
on	on	RP	O
to	to	TO	O
develop	develop	VB	O
symptoms	symptom	NNS	O
of	of	IN	O
post	post	JJ	O
-	-	JJ	O
traumatic	traumatic	JJ	O
stress	stress	NN	O
disorder	disorder	NN	O
,	,	,	O
and	and	CC	O
in	in	IN	O
most	most	JJS	O
of	of	IN	O
these	these	DT	O
cases	case	NNS	O
the	the	DT	O
symptoms	symptom	NNS	O
persist	persist	VBP	O
for	for	IN	O
at	at	IN	O
least	least	JJS	O
a	a	DT	O
year	year	NN	B
.	.	.	O

Pain	pain	NN	O
,	,	,	O
fatigue	fatigue	NN	O
,	,	,	O
arm	arm	NN	O
morbidity	morbidity	NN	O
,	,	,	O
and	and	CC	O
postmenopausal	postmenopausal	JJ	O
symptoms	symptom	NNS	O
were	be	VBD	O
among	among	IN	O
the	the	DT	O
most	most	RBS	O
common	common	JJ	O
symptoms	symptom	NNS	O
are	be	VBP	O
reported	report	VBN	O
by	by	IN	O
breast	breast	NN	O
cancer	cancer	NN	O
patients	patient	NNS	B
.	.	.	O

The	the	DT	O
recognition	recognition	NN	O
and	and	CC	O
treatment	treatment	NN	O
of	of	IN	O
these	these	DT	O
symptoms	symptom	NNS	O
are	be	VBP	O
main	main	JJ	O
issues	issue	NNS	O
since	since	IN	O
these	these	DT	O
symptoms	symptom	NNS	O
impair	impair	VBP	O
health	health	NN	O
-	-	HYPH	O
related	relate	VBN	O
quality	quality	NN	O
of	of	IN	O
life	life	NN	O
.	.	.	O

It	-PRON-	PRP	O
can	can	MD	O
strike	strike	VB	O
at	at	IN	O
any	any	DT	O
age	age	NN	O
,	,	,	O
but	but	CC	O
it	-PRON-	PRP	O
is	be	VBZ	O
commonly	commonly	RB	O
diagnosed	diagnose	VBN	O
in	in	IN	O
middle	middle	NN	O
-	-	HYPH	O
aged	aged	JJ	O
women	woman	NNS	B
.	.	.	O

According	accord	VBG	O
to	to	IN	O
International	International	NNP	O
Agency	Agency	NNP	O
for	for	IN	O
Research	Research	NNP	O
on	on	IN	O
Cancer	Cancer	NNP	O
of	of	IN	O
World	World	NNP	O
Health	Health	NNP	O
Organization	Organization	NNP	O
,	,	,	O
there	there	EX	O
were	be	VBD	O
2.09	2.09	CD	O
million	million	CD	O
cases	case	NNS	O
of	of	IN	O
breast	breast	NN	O
cancer	cancer	NN	O
reported	report	VBD	O
globally	globally	RB	O
,	,	,	O
out	out	IN	O
of	of	IN	O
which	which	WDT	O
627,000	627,000	CD	O
deaths	death	NNS	O
have	have	VBP	O
been	be	VBN	O
occurred	occur	VBN	O
in	in	IN	O
2018	2018	CD	O
.	.	.	O

The	the	DT	O
estimated	estimate	VBN	O
numbers	number	NNS	O
of	of	IN	O
new	new	JJ	O
cases	case	NNS	O
of	of	IN	O
breast	breast	NN	O
cancer	cancer	NN	O
in	in	IN	O
2018	2018	CD	O
in	in	IN	O
the	the	DT	O
USA	USA	NNP	O
were	be	VBD	O
268,670	268,670	CD	O
with	with	IN	O
total	total	JJ	O
41,400	41,400	CD	O
deaths	death	NNS	B
.	.	.	O

The	the	DT	O
breast	breast	NN	O
cancer	cancer	NN	O
mortality	mortality	NN	O
rates	rate	NNS	O
have	have	VBP	O
been	be	VBN	O
declined	decline	VBN	O
in	in	IN	O
the	the	DT	O
past	past	JJ	O
few	few	JJ	O
years	year	NNS	O
owing	owe	VBG	O
to	to	IN	O
early	early	JJ	O
diagnosis	diagnosis	NN	O
and	and	CC	O
advancement	advancement	NN	O
in	in	IN	O
treatments	treatment	NNS	B
.	.	.	O

The	the	DT	O
present	present	JJ	O
medication	medication	NN	O
such	such	JJ	O
as	as	IN	O
endocrine	endocrine	NN	O
therapy	therapy	NN	O
for	for	IN	O
the	the	DT	O
different	different	JJ	O
subtypes	subtype	NNS	O
of	of	IN	O
breast	breast	NN	O
cancer	cancer	NN	O
is	be	VBZ	O
utilised	utilise	VBN	O
for	for	IN	O
the	the	DT	O
treatment	treatment	NN	O
and	and	CC	O
prevention	prevention	NN	O
of	of	IN	O
oestrogen	oestrogen	NN	O
-	-	HYPH	O
receptor	receptor	NN	O
-	-	HYPH	O
positive	positive	JJ	O
breast	breast	NN	O
carcinoma	carcinoma	NN	B
.	.	.	O

The	the	DT	O
ERâ+	ERâ+	NNP	O
and	and	CC	O
human	human	JJ	O
epidermal	epidermal	JJ	O
growth	growth	NN	O
factor	factor	NN	O
receptor	receptor	NN	O
2	2	CD	O
sub	sub	NN	O
types	type	NNS	O
breast	breast	NN	O
cancer	cancer	NN	O
are	be	VBP	O
treated	treat	VBN	O
by	by	IN	O
tamoxifen	tamoxifen	NN	O
and	and	CC	O
monoclonal	monoclonal	JJ	O
antibody	antibody	NN	O
,	,	,	O
respectively	respectively	RB	B
.	.	.	O

Endocrine	endocrine	NN	O
therapy	therapy	NN	O
is	be	VBZ	O
the	the	DT	O
most	most	RBS	O
effective	effective	JJ	O
and	and	CC	O
least	least	JJS	O
toxic	toxic	JJ	O
treatment	treatment	NN	O
for	for	IN	O
breast	breast	NN	O
cancer	cancer	NN	O
,	,	,	O
but	but	CC	O
it	-PRON-	PRP	O
poses	pose	VBZ	O
challenges	challenge	NNS	O
.	.	.	O

The	the	DT	O
major	major	JJ	O
challenges	challenge	NNS	O
are	be	VBP	O
late	late	JJ	O
recurrence	recurrence	NN	O
,	,	,	O
drug	drug	NN	O
resistance	resistance	NN	O
,	,	,	O
painful	painful	JJ	O
injection	injection	NN	O
,	,	,	O
and	and	CC	O
lack	lack	NN	O
of	of	IN	O
compliance	compliance	NN	B
.	.	.	O

The	the	DT	O
increase	increase	NN	O
in	in	IN	O
the	the	DT	O
utilisation	utilisation	NN	O
of	of	IN	O
endocrine	endocrine	NN	O
agents	agent	NNS	O
has	have	VBZ	O
brought	bring	VBN	O
about	about	RP	O
the	the	DT	O
improvement	improvement	NN	O
of	of	IN	O
procedures	procedure	NNS	O
to	to	TO	O
prevent	prevent	VB	O
and	and	CC	O
eradicate	eradicate	VB	O
mammary	mammary	JJ	O
cancer	cancer	NN	O
.	.	.	O

About	about	RB	O
30	30	CD	O
%	%	NN	O
of	of	IN	O
both	both	DT	O
ERâ+âand	ERâ+âand	NNP	O
progesterone	progesterone	NN	O
-	-	HYPH	O
receptor	receptor	NN	O
-	-	HYPH	O
positive	positive	JJ	O
tumours	tumour	NNS	O
are	be	VBP	O
not	not	RB	O
susceptible	susceptible	JJ	O
to	to	TO	O
endocrine	endocrine	VB	O
treatment	treatment	NN	B
.	.	.	O

There	there	EX	O
are	be	VBP	O
limitations	limitation	NNS	O
in	in	IN	O
predicting	predict	VBG	O
the	the	DT	O
efficacy	efficacy	NN	O
of	of	IN	O
endocrine	endocrine	NN	O
treatment	treatment	NN	O
for	for	IN	O
hormone	hormone	NN	O
receptor	receptor	NN	O
expression	expression	NN	O
alone	alone	RB	O
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
the	the	DT	O
combination	combination	NN	O
therapies	therapy	NNS	O
are	be	VBP	O
utmost	utmost	RB	O
needed	need	VBN	O
to	to	TO	O
reduce	reduce	VB	O
the	the	DT	O
chemo	chemo	NN	O
-	-	HYPH	O
resistance	resistance	NN	O
.	.	.	O

It	-PRON-	PRP	O
has	have	VBZ	O
been	be	VBN	O
reported	report	VBN	O
that	that	IN	O
sphingosine-1-phosphate	sphingosine-1-phosphate	NNP	O
,	,	,	O
a	a	DT	O
sphingolipid	sphingolipid	JJ	O
bioactive	bioactive	NN	O
molecule	molecule	NN	O
that	that	WDT	O
mediates	mediate	VBZ	O
various	various	JJ	O
biological	biological	JJ	O
processes	process	NNS	O
plays	play	VBZ	O
a	a	DT	O
key	key	JJ	O
role	role	NN	O
in	in	IN	O
breast	breast	NN	O
carcinoma	carcinoma	NN	B
.	.	.	O

The	the	DT	O
process	process	NN	O
starts	start	VBZ	O
when	when	WRB	O
S1P	S1P	NNP	O
is	be	VBZ	O
produced	produce	VBN	O
intracellularly	intracellularly	RB	O
by	by	IN	O
two	two	CD	O
sphingosine	sphingosine	NN	O
kinases	kinase	NNS	O
such	such	JJ	O
as	as	IN	O
sphingosine	sphingosine	NNP	O
kinase	kinase	VBD	O
1	1	CD	O
and	and	CC	O
SphK2	SphK2	NNP	O
with	with	IN	O
autocrine	autocrine	NN	O
and	and	CC	O
paracrine	paracrine	NN	O
action	action	NN	O
called	call	VBN	O
âinside	âinside	NN	O
out	out	RP	O
signalingâ	signalingâ	NNP	B
,	,	,	B
.	.	.	O

The	the	DT	O
action	action	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
is	be	VBZ	O
mediated	mediate	VBN	O
by	by	IN	O
few	few	JJ	O
developmental	developmental	JJ	O
factors	factor	NNS	O
such	such	JJ	O
as	as	IN	O
oestradiol	oestradiol	NN	O
,	,	,	O
epidermal	epidermal	JJ	O
growth	growth	NN	O
factor	factor	NN	O
,	,	,	O
vitamins	vitamin	NNS	O
and	and	CC	O
cytokines	cytokine	VBZ	O
IL1	IL1	NNP	O
,	,	,	O
and	and	CC	O
IL6	IL6	NNP	B
,	,	,	B
.	.	.	O

The	the	DT	O
active	active	JJ	O
transport	transport	NN	O
of	of	IN	O
S1P	S1P	NNS	O
from	from	IN	O
the	the	DT	O
cell	cell	NN	O
takes	take	VBZ	O
place	place	NN	O
with	with	IN	O
the	the	DT	O
help	help	NN	O
of	of	IN	O
oestradiol	oestradiol	NN	O
via	via	IN	O
ATP	ATP	NNP	O
binding	bind	VBG	O
cassette	cassette	NN	O
transporter	transporter	NN	O
A1	A1	NNP	O
,	,	,	O
ATP	ATP	NNP	O
binding	bind	VBG	O
cassette	cassette	NN	O
transporter	transporter	NN	O
C1	C1	NNP	O
,	,	,	O
and	and	CC	O
ATP	ATP	NNP	O
binding	bind	VBG	O
cassette	cassette	NN	O
transporter	transporter	NN	O
G2	G2	NNP	B
.	.	.	O

The	the	DT	O
S1P	s1p	NN	O
regulates	regulate	VBZ	O
various	various	JJ	O
biological	biological	JJ	O
processes	process	NNS	O
such	such	JJ	O
as	as	IN	O
cell	cell	NN	O
development	development	NN	O
,	,	,	O
anti	anti	JJ	O
-	-	NN	O
apoptosis	apoptosis	JJ	O
,	,	,	O
intrusion	intrusion	NN	O
,	,	,	O
angiogenesis	angiogenesis	NN	O
,	,	,	O
and	and	CC	O
expansion	expansion	NN	O
after	after	IN	O
attaching	attach	VBG	O
to	to	IN	O
five	five	CD	O
selective	selective	JJ	O
G	g	NN	O
protein	protein	NN	O
-	-	HYPH	O
coupled	couple	VBN	O
receptor	receptor	NN	O
located	locate	VBN	O
on	on	IN	O
the	the	DT	O
plasma	plasma	NN	O
membrane	membrane	NN	O
.	.	.	O

This	this	DT	O
in	in	IN	O
turn	turn	NN	O
stimulates	stimulate	VBZ	O
ERK1/2	ERK1/2	.	O
prompting	prompt	VBG	O
downstream	downstream	JJ	O
signalling	signal	VBG	O
that	that	WDT	O
is	be	VBZ	O
a	a	DT	O
crucial	crucial	JJ	O
step	step	NN	O
for	for	IN	O
metastasis	metastasis	NN	O
of	of	IN	O
breast	breast	NN	O
cancer	cancer	NN	B
.	.	.	O

Apart	apart	RB	O
from	from	IN	O
regulating	regulate	VBG	O
ERK1/2	ERK1/2	.	O
pathway	pathway	NNP	O
,	,	,	O
it	-PRON-	PRP	O
also	also	RB	O
mediates	mediate	VBZ	O
PI3K	PI3K	NNP	O
/	/	SYM	O
AKT	AKT	NNP	O
signalling	signal	VBG	O
pathway	pathway	JJ	B
.	.	.	O

It	-PRON-	PRP	O
has	have	VBZ	O
been	be	VBN	O
well	well	RB	O
documented	document	VBN	O
that	that	IN	O
high	high	JJ	O
expression	expression	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
is	be	VBZ	O
associated	associate	VBN	O
with	with	IN	O
different	different	JJ	O
subsets	subset	NNS	O
of	of	IN	O
breast	breast	NN	O
carcinoma	carcinoma	NN	O
such	such	JJ	O
as	as	IN	O
ER+	ER+	NNP	O
,	,	,	O
HER	her	PRP$	O
2	2	CD	O
,	,	,	O
and	and	CC	O
TNBC	tnbc	NN	O
,	,	,	O
thereby	thereby	RB	O
resulting	result	VBG	O
the	the	DT	O
worse	bad	JJR	O
prognosis	prognosis	NN	O
and	and	CC	O
resistance	resistance	NN	O
to	to	IN	O
available	available	JJ	O
antitumour	antitumour	NN	O
therapies	therapy	NNS	B
,	,	,	B
.	.	.	O

Various	various	JJ	O
inhibitors	inhibitor	NNS	O
of	of	IN	O
SphK1	SphK1	NNP	O
such	such	JJ	O
as	as	IN	O
PF-543	PF-543	NNP	O
,	,	,	O
SK1	SK1	NNP	O
-	-	HYPH	O
5c	5c	NNP	O
,	,	,	O
Belanocarpol	Belanocarpol	NNP	O
,	,	,	O
RB-005	RB-005	NNP	O
,	,	,	O
and	and	CC	O
VPC96091	vpc96091	NN	O
have	have	VBP	O
been	be	VBN	O
designed	design	VBN	O
so	so	RB	O
far	far	RB	O
,	,	,	O
but	but	CC	O
to	to	TO	O
identify	identify	VB	O
the	the	DT	O
finest	fine	JJS	O
one	one	CD	O
having	have	VBG	O
plausible	plausible	JJ	O
bioavailability	bioavailability	NN	O
,	,	,	O
pharmacokinetic	pharmacokinetic	JJ	O
,	,	,	O
and	and	CC	O
pharmacodynamic	pharmacodynamic	JJ	O
properties	property	NNS	O
is	be	VBZ	O
yet	yet	RB	O
to	to	TO	O
be	be	VB	O
developed	develop	VBN	B
,	,	,	B
.	.	.	O

The	the	DT	O
main	main	JJ	O
objective	objective	NN	O
of	of	IN	O
present	present	JJ	O
work	work	NN	O
is	be	VBZ	O
to	to	TO	O
identify	identify	VB	O
a	a	DT	O
potent	potent	JJ	O
lead	lead	NN	O
compound	compound	NN	O
against	against	IN	O
breast	breast	NN	O
cancer	cancer	NN	O
using	use	VBG	O
several	several	JJ	O
computational	computational	JJ	O
approaches	approach	NNS	O
such	such	JJ	O
as	as	IN	O
the	the	DT	O
ligand	ligand	NN	O
-	-	HYPH	O
based	base	VBN	O
virtual	virtual	JJ	O
screening	screening	NN	B
,	,	,	O
molecular	molecular	JJ	O
docking	dock	VBG	B
,	,	,	O
molecular	molecular	JJ	O
dynamics	dynamic	NNS	O
simulations	simulation	NNS	B
,	,	,	O
and	and	CC	O
the	the	DT	O
molecular	molecular	JJ	O
mechanics	mechanic	NNS	O
PoissonâBoltzmann	PoissonâBoltzmann	NNP	O
surface	surface	NN	O
area	area	NN	O
calculations	calculation	NNS	B
.	.	.	O

The	the	DT	O
molecular	molecular	JJ	O
interaction	interaction	NN	O
studies	study	NNS	O
of	of	IN	O
predicted	predict	VBN	O
lead	lead	NN	O
molecules	molecule	NNS	O
with	with	IN	O
target	target	NN	O
protein	protein	NN	O
SphK1	SphK1	NNP	O
were	be	VBD	O
also	also	RB	O
carried	carry	VBN	O
out	out	RP	O
in	in	IN	O
order	order	NN	O
to	to	TO	O
check	check	VB	O
the	the	DT	O
strength	strength	NN	O
of	of	IN	O
drug	drug	NN	O
binding	binding	NN	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
were	be	VBD	O
further	further	RB	O
compared	compare	VBN	O
with	with	IN	O
known	know	VBN	O
inhibitor	inhibitor	NN	O
PF-543	PF-543	NNP	B
,	,	,	O
and	and	CC	O
the	the	DT	O
best	good	JJS	O
drug	drug	NN	O
was	be	VBD	O
identified	identify	VBN	O
.	.	.	O

This	this	DT	O
study	study	NN	O
may	may	MD	O
provide	provide	VB	O
valuable	valuable	JJ	O
insight	insight	NN	O
leading	lead	VBG	O
to	to	IN	O
improved	improved	JJ	O
treatment	treatment	NN	O
of	of	IN	O
patients	patient	NNS	O
with	with	IN	O
breast	breast	NN	O
cancer	cancer	NN	O
.	.	.	O

The	the	DT	O
3D	3d	JJ	O
structure	structure	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
in	in	IN	O
complex	complex	NN	O
with	with	IN	O
PF-543	PF-543	NNP	O
was	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
RCSB	RCSB	NNP	O
Protein	Protein	NNP	O
Data	Data	NNPS	O
Bank	Bank	NNP	B
.	.	.	O

The	the	DT	O
coordinates	coordinate	NNS	O
of	of	IN	O
heteroatoms	heteroatom	NNS	O
were	be	VBD	O
removed	remove	VBN	O
to	to	TO	O
prepare	prepare	VB	O
the	the	DT	O
protein	protein	NN	O
for	for	IN	O
molecular	molecular	JJ	O
docking	docking	NN	O
.	.	.	O

The	the	DT	O
energy	energy	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
was	be	VBD	O
minimised	minimise	VBN	O
by	by	IN	O
applying	apply	VBG	O
the	the	DT	O
CHARMm	CHARMm	NNP	O
force	force	NN	O
field	field	NN	O
.	.	.	O

The	the	DT	O
active	active	JJ	O
site	site	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
was	be	VBD	O
located	locate	VBN	O
for	for	IN	O
ligand	ligand	NN	O
binding	bind	VBG	O
where	where	WRB	O
the	the	DT	O
inhibitor	inhibitor	NN	O
PF-543	PF-543	NNP	O
was	be	VBD	O
co	co	VBN	O
-	-	VBN	O
crystallised	crystallised	JJ	B
.	.	.	O

SwissSimilarity	SwissSimilarity	NNP	B
,	,	,	O
a	a	DT	O
novel	novel	NN	O
web	web	NN	O
-	-	HYPH	O
based	base	VBN	O
tool	tool	NN	O
that	that	WDT	O
offers	offer	VBZ	O
ultra	ultra	JJ	O
-	-	JJ	O
high	high	JJ	O
-	-	HYPH	O
throughput	throughput	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
from	from	IN	O
various	various	JJ	O
repositories	repository	NNS	O
of	of	IN	O
chemical	chemical	JJ	O
compounds	compound	NNS	O
such	such	JJ	O
as	as	IN	O
DrugBank	DrugBank	NNP	B
,	,	,	O
Ligand	Ligand	NNP	O
Expo	Expo	NNP	B
,	,	,	O
ChEMBL	chembl	NN	B
,	,	,	O
ChEBI	ChEBI	NNP	B
,	,	,	O
GLASS	GLASS	NNP	B
,	,	,	O
the	the	DT	O
Human	Human	NNP	O
Metabolome	Metabolome	NNP	O
Database	Database	NNP	B
,	,	,	O
and	and	CC	O
ZINC	ZINC	NNP	O
databases	database	VBZ	B
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
perform	perform	VB	O
LBVS	LBVS	NNP	O
.	.	.	O

The	the	DT	O
predictions	prediction	NNS	O
were	be	VBD	O
based	base	VBN	O
on	on	IN	O
five	five	CD	O
different	different	JJ	O
2D	2d	NN	O
and	and	CC	O
3D	3d	NN	O
search	search	NN	O
techniques	technique	NNS	O
,	,	,	O
namely	namely	RB	O
molecular	molecular	JJ	O
fingerprints	fingerprint	NNS	O
,	,	,	O
electroshape	electroshape	NN	O
,	,	,	O
spectrophores	spectrophore	NNS	O
,	,	,	O
shape	shape	NN	O
IT	it	NN	O
,	,	,	O
and	and	CC	O
align	align	VB	O
IT	it	PRP	O
.	.	.	O

The	the	DT	O
screening	screening	NN	O
by	by	IN	O
these	these	DT	O
approaches	approach	NNS	O
are	be	VBP	O
based	base	VBN	O
on	on	IN	O
similarity	similarity	NN	O
score	score	NN	O
such	such	JJ	O
as	as	IN	O
1	1	CD	O
for	for	IN	O
similar	similar	JJ	O
and	and	CC	O
0	0	CD	O
for	for	IN	O
dissimilar	dissimilar	JJ	O
compounds	compound	NNS	O
.	.	.	O

Different	different	JJ	O
filters	filter	NNS	O
were	be	VBD	O
applied	apply	VBN	O
to	to	TO	O
predict	predict	VB	O
hits	hit	NNS	O
based	base	VBN	O
on	on	IN	O
Lipinskiâs	Lipinskiâs	NNP	O
RO5	RO5	NNP	B
,	,	,	B
,	,	,	O
Veber	Veber	NNP	B
,	,	,	O
Ghose	Ghose	NNP	B
,	,	,	O
Egan	Egan	NNP	B
,	,	,	O
Muegge	Muegge	NNP	B
,	,	,	O
lead	lead	JJ	O
likeness	likeness	NN	O
,	,	,	O
and	and	CC	O
pan	pan	NN	O
-	-	HYPH	O
assay	assay	NNP	O
interference	interference	NN	O
compounds	compound	VBZ	O
analysis	analysis	NN	B
.	.	.	O

In	in	IN	O
RO5	RO5	NNP	O
,	,	,	O
the	the	DT	O
attributes	attribute	NNS	O
commonly	commonly	RB	O
found	find	VBN	O
in	in	IN	O
orally	orally	RB	O
active	active	JJ	O
drug	drug	NN	O
molecules	molecule	NNS	O
of	of	IN	O
molecular	molecular	JJ	O
weight	weight	NN	O
â¤500âDa	â¤500âDa	NNP	O
,	,	,	O
hydrogen	hydrogen	NNP	O
bond	bond	NN	O
acceptor	acceptor	NN	O
â¤10	â¤10	NNP	O
,	,	,	O
hydrogen	hydrogen	NN	O
bond	bond	NN	O
donor	donor	NN	O
5â¤	5â¤	CD	O
,	,	,	O
and	and	CC	O
log	log	NN	O
P	P	NNP	O
â¤5	â¤5	NNP	O
.	.	.	O

Veber	Veber	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

improved	improve	VBD	O
the	the	DT	O
RO5	RO5	NNP	O
with	with	IN	O
the	the	DT	O
addition	addition	NN	O
of	of	IN	O
two	two	CD	O
more	more	JJR	O
properties	property	NNS	O
including	include	VBG	O
the	the	DT	O
number	number	NN	O
of	of	IN	O
rotatable	rotatable	JJ	O
bonds	bond	NNS	O
â¤10	â¤10	NNP	O
and	and	CC	O
PSA	PSA	NNP	O
â¤140Â	â¤140Â	NNP	O
Ã	Ã	NNP	O
		_SP	O
2	2	CD	O
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
the	the	DT	O
RO5	RO5	NNP	O
fails	fail	VBZ	O
to	to	TO	O
explain	explain	VB	O
the	the	DT	O
basic	basic	JJ	O
highlights	highlight	NNS	O
found	find	VBN	O
in	in	IN	O
drugs	drug	NNS	O
or	or	CC	O
non	non	NNS	O
-	-	NNS	O
drugs	drug	NNS	O
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
Ghose	Ghose	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

expanded	expand	VBD	O
this	this	DT	O
work	work	NN	O
in	in	IN	O
view	view	NN	O
of	of	IN	O
processed	process	VBN	O
physicochemical	physicochemical	JJ	O
properties	property	NNS	O
.	.	.	O

They	-PRON-	PRP	O
set	set	VBD	O
up	up	RP	O
the	the	DT	O
accompanying	accompany	VBG	O
criteria	criterion	NNS	O
such	such	JJ	O
as	as	IN	O
A	a	DT	O
log	log	NN	O
P	p	NN	O
â0.4	â0.4	NNP	O
to	to	IN	O
5.6	5.6	CD	O
,	,	,	O
molar	molar	JJ	O
refractivity	refractivity	NN	O
40â130	40â130	CD	O
,	,	,	O
molecular	molecular	JJ	O
weight	weight	NN	O
160â480	160â480	CD	O
,	,	,	O
and	and	CC	O
the	the	DT	O
number	number	NN	O
of	of	IN	O
atoms	atom	NNS	O
20â70	20â70	CD	O
.	.	.	O

Further	further	RB	O
,	,	,	O
Muegge	Muegge	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

assigned	assign	VBD	O
a	a	DT	O
score	score	NN	O
due	due	IN	O
to	to	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
structural	structural	JJ	O
fragments	fragment	NNS	O
on	on	IN	O
a	a	DT	O
molecule	molecule	NN	O
that	that	WDT	O
are	be	VBP	O
typically	typically	RB	O
found	find	VBN	O
in	in	IN	O
drugs	drug	NNS	O
.	.	.	O

The	the	DT	O
molecules	molecule	NNS	O
with	with	IN	O
a	a	DT	O
score	score	NN	O
ranging	range	VBG	O
from	from	IN	O
2	2	CD	O
to	to	IN	O
7	7	CD	O
were	be	VBD	O
classified	classify	VBN	O
as	as	IN	O
drugs	drug	NNS	O
.	.	.	O

Two	two	CD	O
main	main	JJ	O
criteria	criterion	NNS	O
namely	namely	RB	O
SLogP	SLogP	VBZ	O
â¤6	â¤6	NNP	O
and	and	CC	O
TPSA	TPSA	NNP	O
â¤132Â	â¤132Â	NFP	O
Ã	Ã	NNP	O
		_SP	O
2	2	CD	O
were	be	VBD	O
further	further	RB	O
included	include	VBN	O
in	in	IN	O
Egan	Egan	NNP	O
filtration	filtration	NN	O
.	.	.	O

All	all	PDT	O
the	the	DT	O
drug	drug	NN	O
likeness	likeness	NN	O
,	,	,	O
lead	lead	JJ	O
likeness	likeness	NN	O
,	,	,	O
and	and	CC	O
pan	pan	NNP	O
assay	assay	NNP	O
interference	interference	NN	O
studies	study	NNS	O
of	of	IN	O
ligands	ligand	NNS	O
and	and	CC	O
standard	standard	JJ	O
molecule	molecule	NN	O
were	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
using	use	VBG	O
SwissADME	swissadme	CD	O
tool	tool	NN	B
.	.	.	O

Absorption	absorption	NN	O
,	,	,	O
distribution	distribution	NN	O
,	,	,	O
metabolism	metabolism	NN	O
,	,	,	O
and	and	CC	O
excretion	excretion	NN	O
and	and	CC	O
toxicity	toxicity	NN	O
assessment	assessment	NN	O
are	be	VBP	O
very	very	RB	O
important	important	JJ	O
part	part	NN	O
of	of	IN	O
leads	lead	NNS	O
selection	selection	NN	O
.	.	.	O

The	the	DT	O
ADME	ADME	NNP	O
and	and	CC	O
toxicity	toxicity	NN	O
parameters	parameter	NNS	O
of	of	IN	O
all	all	DT	O
compounds	compound	NNS	O
obtained	obtain	VBN	O
after	after	IN	O
filtration	filtration	NN	O
on	on	IN	O
various	various	JJ	O
parameters	parameter	NNS	O
of	of	IN	O
drug	drug	NN	O
likeness	likeness	NN	O
properties	property	NNS	O
were	be	VBD	O
checked	check	VBN	O
using	use	VBG	O
TOxicity	TOxicity	NNP	O
Prediction	Prediction	NNP	O
by	by	IN	O
Komputer	Komputer	NNP	O
Assisted	Assisted	NNP	O
Technology	Technology	NNP	O
module	module	NN	O
of	of	IN	O
Discovery	Discovery	NNP	O
studio	studio	NN	O
2.5	2.5	CD	O
.	.	.	O

This	this	DT	O
tool	tool	NN	O
predicts	predict	VBZ	O
the	the	DT	O
toxicity	toxicity	NN	O
using	use	VBG	O
weight	weight	NN	O
of	of	IN	O
the	the	DT	O
evidence	evidence	NN	O
parameter	parameter	NN	O
of	of	IN	O
carcinogenicity	carcinogenicity	NN	O
as	as	IN	O
per	per	IN	O
the	the	DT	O
Food	Food	NNP	O
and	and	CC	O
Drug	Drug	NNP	O
Administration	Administration	NNP	O
and	and	CC	O
National	National	NNP	O
Toxicology	Toxicology	NNP	O
Program	Program	NNP	O
animal	animal	NN	O
model	model	NN	O
guidelines	guideline	NNS	O
.	.	.	O

AutoDock	AutoDock	NNP	O
4.2	4.2	CD	B
molecular	molecular	JJ	O
docking	docking	NN	O
software	software	NN	O
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
identify	identify	VB	O
the	the	DT	O
most	most	RBS	O
probable	probable	JJ	O
binding	binding	NN	O
pose	pose	NN	O
and	and	CC	O
molecular	molecular	JJ	O
interactions	interaction	NNS	O
of	of	IN	O
inhibitors	inhibitor	NNS	O
into	into	IN	O
the	the	DT	O
active	active	JJ	O
pocket	pocket	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
.	.	.	O

In	in	IN	O
this	this	DT	O
trend	trend	NN	O
,	,	,	O
we	-PRON-	PRP	O
addressed	address	VBD	O
protein	protein	NN	O
preparation	preparation	NN	O
,	,	,	O
chain	chain	NN	O
selection	selection	NN	O
,	,	,	O
and	and	CC	O
non	non	JJ	O
-	-	JJ	O
protein	protein	JJ	O
parts	part	NNS	O
deletion	deletion	NN	O
with	with	IN	O
Discovery	Discovery	NNP	O
Studio	Studio	NNP	O
Visualizer	Visualizer	NNP	O
2.5	2.5	CD	O
.	.	.	O

For	for	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
a	a	DT	O
grid	grid	NN	O
was	be	VBD	O
set	set	VBN	O
up	up	RP	O
with	with	IN	O
60âÃâ60âÃâ60	60âãâ60âãâ60	CD	O
points	point	NNS	O
,	,	,	O
and	and	CC	O
docking	docking	NN	O
was	be	VBD	O
performed	perform	VBN	O
by	by	IN	O
using	use	VBG	O
default	default	NN	O
parameters	parameter	NNS	O
.	.	.	O

The	the	DT	O
ligands	ligand	NNS	O
were	be	VBD	O
docked	dock	VBN	O
into	into	IN	O
the	the	DT	O
active	active	JJ	O
pocket	pocket	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
where	where	WRB	O
the	the	DT	O
inhibitor	inhibitor	NN	O
PF-543	PF-543	NNP	O
was	be	VBD	O
present	present	JJ	B
.	.	.	O

The	the	DT	O
proper	proper	JJ	O
orientations	orientation	NNS	O
of	of	IN	O
docked	dock	VBN	O
molecules	molecule	NNS	O
in	in	IN	O
SphK1	SphK1	NNP	O
were	be	VBD	O
selected	select	VBN	O
.	.	.	O

The	the	DT	O
compounds	compound	NNS	O
having	have	VBG	O
least	least	JJS	O
ÎG	îg	JJ	O
values	value	NNS	O
were	be	VBD	O
treated	treat	VBN	O
as	as	IN	O
strong	strong	JJ	O
binding	bind	VBG	O
affinity	affinity	NN	O
with	with	IN	O
the	the	DT	O
target	target	NN	O
protein	protein	NN	O
.	.	.	O

MD	MD	NNP	O
simulations	simulation	NNS	O
were	be	VBD	O
performed	perform	VBN	O
on	on	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
SphK1âPF-543	SphK1âPF-543	NNP	O
,	,	,	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
,	,	,	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
,	,	,	O
and	and	CC	O
SphK1âZINC95421501	sphk1âzinc95421501	VB	O
at	at	IN	O
300Â	300â	CD	O
K	K	NNP	O
at	at	IN	O
the	the	DT	O
MM	MM	NNP	O
level	level	NN	O
executed	execute	VBN	O
by	by	IN	O
GROMACS	GROMACS	NNP	O
5.1.2	5.1.2	CD	B
utilising	utilise	VBG	O
the	the	DT	O
GROMOS96	GROMOS96	NNP	O
43a1	43a1	CD	O
force	force	NN	O
-	-	HYPH	O
field	field	NN	O
.	.	.	O

The	the	DT	O
ligands	ligand	NNS	O
were	be	VBD	O
extracted	extract	VBN	O
from	from	IN	O
the	the	DT	O
docked	docked	JJ	O
complexes	complex	NNS	O
utilising	utilise	VBG	O
gmx	gmx	NNP	O
grep	grep	NNP	O
module	module	NN	O
.	.	.	O

The	the	DT	O
topology	topology	NN	O
and	and	CC	O
force	force	NN	O
-	-	HYPH	O
field	field	NN	O
parameter	parameter	NN	O
files	file	NNS	O
of	of	IN	O
the	the	DT	O
ligands	ligand	NNS	O
were	be	VBD	O
obtained	obtain	VBN	O
by	by	IN	O
PRODRG	prodrg	NN	O
server	server	NN	B
.	.	.	O

The	the	DT	O
charges	charge	NNS	O
in	in	IN	O
the	the	DT	O
topology	topology	NN	O
file	file	NN	O
were	be	VBD	O
manually	manually	RB	O
corrected	correct	VBN	O
.	.	.	O

The	the	DT	O
topologies	topology	NNS	O
were	be	VBD	O
generated	generate	VBN	O
for	for	IN	O
SphK1	SphK1	NNP	O
utilising	utilise	VBG	O
pdb2gmx	pdb2gmx	NN	O
modules	module	NNS	O
of	of	IN	O
gromacs	gromacs	NNP	O
and	and	CC	O
PF-543	PF-543	NNP	O
,	,	,	O
ZINC06823429	ZINC06823429	NNP	O
,	,	,	O
ZINC95421070	zinc95421070	ADD	O
,	,	,	O
and	and	CC	O
ZINC95421501	zinc95421501	XX	O
using	use	VBG	O
PRODRG	PRODRG	NNP	O
server	server	NN	O
were	be	VBD	O
merged	merge	VBN	O
together	together	RB	O
.	.	.	O

The	the	DT	O
extra	extra	JJ	O
ligand	ligand	NN	O
atoms	atom	NNS	O
were	be	VBD	O
combined	combine	VBN	O
in	in	IN	O
the	the	DT	O
complex	complex	JJ	O
topologies	topology	NNS	O
with	with	IN	O
default	default	NN	O
parameters	parameter	NNS	O
.	.	.	O

The	the	DT	O
SphK1	SphK1	NNP	O
,	,	,	O
SphK1âPF-543	SphK1âPF-543	NNP	O
,	,	,	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
,	,	,	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
,	,	,	O
and	and	CC	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
were	be	VBD	O
soaked	soak	VBN	O
in	in	IN	O
a	a	DT	O
cubic	cubic	JJ	O
box	box	NN	O
of	of	IN	O
water	water	NN	O
molecules	molecule	NNS	O
with	with	IN	O
a	a	DT	O
dimension	dimension	NN	O
of	of	IN	O
10Â	10Â	NNP	O
Ã	Ã	NNP	O
		_SP	O
,	,	,	O
i.e.	i.e.	FW	O
setting	set	VBG	O
the	the	DT	O
edge	edge	NN	O
10Â	10Â	NNP	O
Ã	ã	VB	O
from	from	IN	O
the	the	DT	O
molecule	molecule	JJ	O
periphery	periphery	NN	O
utilising	utilise	VBG	O
the	the	DT	O
gmx	gmx	NNP	O
editconf	editconf	NNP	O
module	module	NN	O
for	for	IN	O
creating	create	VBG	O
boundary	boundary	JJ	O
conditions	condition	NNS	O
and	and	CC	O
gmx	gmx	JJ	O
solvate	solvate	JJ	O
module	module	NN	O
for	for	IN	O
solvation	solvation	NN	O
.	.	.	O

The	the	DT	O
Simple	Simple	NNP	O
Point	Point	NNP	O
Charge	Charge	NNP	O
water	water	NN	O
model	model	NN	O
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
solvate	solvate	VB	O
the	the	DT	O
system	system	NN	O
.	.	.	O

The	the	DT	O
charges	charge	NNS	O
on	on	IN	O
the	the	DT	O
SphK1	SphK1	NNP	O
,	,	,	O
SphK1âPF-543	SphK1âPF-543	NNP	O
,	,	,	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
,	,	,	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
,	,	,	O
and	and	CC	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
complexes	complex	NNS	O
were	be	VBD	O
neutralised	neutralise	VBN	O
by	by	IN	O
addition	addition	NN	O
of	of	IN	O
Na+	Na+	NNP	O
and	and	CC	O
Clâ	Clâ	NNP	O
ions	ion	NNS	O
using	use	VBG	O
gmx	gmx	NNP	O
genion	genion	NN	O
module	module	NN	O
to	to	TO	O
maintain	maintain	VB	O
neutrality	neutrality	NN	O
,	,	,	O
preserving	preserve	VBG	O
a	a	DT	O
physiological	physiological	JJ	O
concentration	concentration	NN	O
of	of	IN	O
0.15Â	0.15Â	NNP	O
M.	M.	NNP	O
Further	Further	NNP	O
,	,	,	O
energy	energy	NN	O
groups	group	NNS	O
were	be	VBD	O
used	use	VBN	O
to	to	TO	O
examine	examine	VB	O
the	the	DT	O
interaction	interaction	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
with	with	IN	O
PF-543	PF-543	NNP	O
,	,	,	O
ZINC06823429	ZINC06823429	NNP	O
,	,	,	O
ZINC95421070	zinc95421070	ADD	O
,	,	,	O
and	and	CC	O
ZINC95421501	zinc95421501	ADD	O
.	.	.	O

The	the	DT	O
system	system	NN	O
was	be	VBD	O
then	then	RB	O
minimised	minimise	VBN	O
using	use	VBG	O
1500	1500	CD	O
steps	step	NNS	O
of	of	IN	O
steepest	steep	JJS	O
descent	descent	NN	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
system	system	NN	O
temperatures	temperature	NNS	O
were	be	VBD	O
raised	raise	VBN	O
from	from	IN	O
0	0	CD	O
to	to	IN	O
300Â	300â	CD	O
K	K	NNP	O
during	during	IN	O
their	-PRON-	PRP$	O
equilibration	equilibration	NN	O
period	period	NN	O
100âps	100âps	CD	O
at	at	IN	O
a	a	DT	O
constant	constant	JJ	O
volume	volume	NN	O
under	under	IN	O
periodic	periodic	JJ	O
boundary	boundary	JJ	O
conditions	condition	NNS	O
.	.	.	O

The	the	DT	O
systems	system	NNS	O
were	be	VBD	O
equilibrated	equilibrate	VBN	O
using	use	VBG	O
NVT	NVT	NNP	O
ensemble	ensemble	JJ	O
constant	constant	JJ	O
number	number	NN	O
of	of	IN	O
particles	particle	NNS	O
,	,	,	O
volume	volume	NN	O
,	,	,	O
and	and	CC	O
temperature	temperature	NN	O
at	at	IN	O
100âps	100âps	CD	O
and	and	CC	O
NPT	NPT	NNP	O
ensemble	ensemble	JJ	O
constant	constant	JJ	O
number	number	NN	O
of	of	IN	O
particles	particle	NNS	O
,	,	,	O
pressure	pressure	NN	O
,	,	,	O
and	and	CC	O
temperature	temperature	NN	O
at	at	IN	O
100âps	100âps	CD	O
.	.	.	O

In	in	IN	O
both	both	DT	O
cases	case	NNS	O
,	,	,	O
the	the	DT	O
CÎ±	cî±	JJ	O
backbone	backbone	NN	O
atoms	atom	NNS	O
of	of	IN	O
the	the	DT	O
original	original	JJ	O
crystal	crystal	NN	O
structure	structure	NN	O
were	be	VBD	O
limited	limit	VBN	O
with	with	IN	O
all	all	DT	O
other	other	JJ	O
atoms	atom	NNS	O
permitted	permit	VBN	O
to	to	TO	O
move	move	VB	O
freely	freely	RB	O
.	.	.	O

After	after	IN	O
the	the	DT	O
equilibration	equilibration	NN	O
phase	phase	NN	O
,	,	,	O
the	the	DT	O
particle	particle	NN	O
-	-	HYPH	O
mesh	mesh	NNP	O
was	be	VBD	O
applied	apply	VBN	O
following	follow	VBG	O
Ewald	Ewald	NNP	O
method	method	NN	O
.	.	.	O

The	the	DT	O
resulting	result	VBG	O
path	path	NN	O
was	be	VBD	O
analysed	analyse	VBN	O
utilising	utilise	VBG	O
gmx	gmx	NN	O
energy	energy	NN	O
,	,	,	O
gmx	gmx	NNP	O
rms	rms	NNP	O
,	,	,	O
gmx	gmx	NNP	O
confirms	confirm	VBZ	O
,	,	,	O
gmx	gmx	NNP	O
rmsf	rmsf	NN	O
,	,	,	O
gmx	gmx	NNP	O
gyrate	gyrate	NN	O
,	,	,	O
make_ndx	make_ndx	NN	O
,	,	,	O
gmx	gmx	NNP	O
hbond	hbond	NN	O
,	,	,	O
gmx	gmx	NNP	O
do_dssp	do_dssp	VBP	O
,	,	,	O
gmx	gmx	NNP	O
covar	covar	JJ	O
,	,	,	O
gmx	gmx	NNP	O
anaeig	anaeig	NNP	O
,	,	,	O
gmx	gmx	NNP	O
sham	sham	NNP	O
,	,	,	O
and	and	CC	O
gmx	gmx	NNP	O
sasa	sasa	NNP	O
utilities	utility	NNS	O
of	of	IN	O
GROMACS	GROMACS	NNP	O
.	.	.	O

The	the	DT	O
plots	plot	NNS	O
of	of	IN	O
the	the	DT	O
3D	3D	NNP	O
models	model	NNS	O
were	be	VBD	O
readied	readie	VBN	O
utilising	utilise	VBG	O
PyMol	PyMol	NNP	O
and	and	CC	O
VMD	VMD	NNP	B
.	.	.	O

The	the	DT	O
details	detail	NNS	O
of	of	IN	O
MD	MD	NNP	O
simulation	simulation	NN	O
method	method	NN	O
were	be	VBD	O
previously	previously	RB	O
described	describe	VBN	B
.	.	.	O

Molecular	molecular	JJ	O
mechanics	mechanic	NNS	O
PoissonâBoltzmann	PoissonâBoltzmann	NNP	O
surface	surface	NN	O
area	area	NN	O
,	,	,	O
a	a	DT	O
strategy	strategy	NN	O
to	to	TO	O
appraise	appraise	VB	O
interaction	interaction	NN	O
free	free	JJ	O
energies	energy	NNS	O
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
study	study	VB	O
bimolecular	bimolecular	JJ	O
interactions	interaction	NNS	O
.	.	.	O

The	the	DT	O
binding	bind	VBG	O
energy	energy	NN	O
was	be	VBD	O
calculated	calculate	VBN	O
utilising	utilise	VBG	O
MMPBSA	MMPBSA	NNP	O
protocols	protocol	NNS	O
implemented	implement	VBN	O
in	in	IN	O
the	the	DT	O
g_mmpbsa	g_mmpbsa	NNP	O
package	package	NN	B
.	.	.	O

A	a	DT	O
proteinâligand	proteinâligand	NNP	O
snapshot	snapshot	NN	O
of	of	IN	O
MD	MD	NNP	O
trajectories	trajectory	NNS	O
between	between	IN	O
40	40	CD	O
and	and	CC	O
50âns	50âns	CD	O
was	be	VBD	O
extracted	extract	VBN	O
from	from	IN	O
the	the	DT	O
stable	stable	JJ	O
region	region	NN	O
of	of	IN	O
every	every	DT	O
complex	complex	NN	O
.	.	.	O

The	the	DT	O
aim	aim	NN	O
was	be	VBD	O
to	to	TO	O
incorporate	incorporate	VB	O
high	high	JJ	O
throughput	throughput	NN	O
MD	MD	NNP	O
simulations	simulation	NNS	O
with	with	IN	O
their	-PRON-	PRP$	O
binding	bind	VBG	O
energy	energy	NN	O
calculations	calculation	NNS	O
.	.	.	O

The	the	DT	O
binding	bind	VBG	O
energies	energy	NNS	O
were	be	VBD	O
figured	figure	VBN	O
utilising	utilise	VBG	O
following	following	JJ	O
equation	equation	NN	O
:	:	:	O
ÎGBinding	îgbinde	VBG	O
=	=	SYM	O
GComplexâwhere	gcomplexâwhere	RB	O
GComplex	GComplex	NNP	O
,	,	,	O
GProtein	GProtein	NNP	O
,	,	,	O
and	and	CC	O
GLigand	GLigand	NNP	O
signify	signify	VBP	O
the	the	DT	O
total	total	JJ	O
free	free	JJ	O
energy	energy	NN	O
of	of	IN	O
the	the	DT	O
binding	bind	VBG	O
complex	complex	NN	O
,	,	,	O
total	total	JJ	O
free	free	JJ	O
energies	energy	NNS	O
of	of	IN	O
the	the	DT	O
individual	individual	JJ	O
protein	protein	NN	O
,	,	,	O
and	and	CC	O
total	total	JJ	O
free	free	JJ	O
energies	energy	NNS	O
of	of	IN	O
the	the	DT	O
individual	individual	JJ	O
ligand	ligand	NN	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

Besides	besides	RB	O
,	,	,	O
the	the	DT	O
free	free	JJ	O
energy	energy	NN	O
for	for	IN	O
each	each	DT	O
individual	individual	JJ	O
entity	entity	NN	O
can	can	MD	O
be	be	VB	O
given	give	VBN	O
by	by	IN	O
:	:	:	O
Gx	gx	IN	O
=	=	IN	O
ãEMMãâTS+ãGsolvationã	ãEMMãâTS+ãGsolvationã	NNS	O
where	where	WRB	O
âxâ	âxâ	NNP	O
is	be	VBZ	O
the	the	DT	O
protein	protein	NN	O
or	or	CC	O
ligand	ligand	NNP	O
or	or	CC	O
proteinâligand	proteinâligand	NNP	O
complex	complex	NN	O
.	.	.	O

EMM	EMM	NNP	O
is	be	VBZ	O
the	the	DT	O
average	average	JJ	O
MM	mm	NN	O
potential	potential	JJ	O
energy	energy	NN	O
in	in	IN	O
a	a	DT	O
vacuum	vacuum	NN	O
.	.	.	O

Temperature	temperature	NN	O
and	and	CC	O
entropy	entropy	JJ	O
jointly	jointly	RB	O
denote	denote	VB	O
the	the	DT	O
entropic	entropic	JJ	O
contribution	contribution	NN	O
to	to	IN	O
the	the	DT	O
free	free	JJ	O
energy	energy	NN	O
in	in	IN	O
a	a	DT	O
vacuum	vacuum	NN	O
and	and	CC	O
the	the	DT	O
Gsolvation	Gsolvation	NNP	O
is	be	VBZ	O
the	the	DT	O
free	free	JJ	O
energy	energy	NN	O
of	of	IN	O
solvation	solvation	NN	O
.	.	.	O

The	the	DT	O
vacuum	vacuum	NN	O
potential	potential	JJ	O
energy	energy	NN	O
is	be	VBZ	O
the	the	DT	O
sum	sum	NN	O
of	of	IN	O
bonded	bond	VBN	O
as	as	RB	O
well	well	RB	O
as	as	IN	O
non	non	JJ	O
-	-	JJ	O
bonded	bonded	JJ	O
interactions	interaction	NNS	O
,	,	,	O
and	and	CC	O
it	-PRON-	PRP	O
is	be	VBZ	O
calculated	calculate	VBN	O
based	base	VBN	O
on	on	IN	O
the	the	DT	O
MM	MM	NNP	O
force	force	NN	O
-	-	HYPH	O
field	field	NN	O
parameters	parameter	NNS	O
.	.	.	O

EMM	EMM	NNP	O
=	=	SYM	O
Ebonded+Enon	Ebonded+Enon	NNP	O
-	-	HYPH	O
bonded	bond	VBN	O
=	=	-RRB-	O
Ebonded+where	Ebonded+where	NNP	O
Ebonded	ebonde	VBN	O
is	be	VBZ	O
bonded	bond	VBN	O
interactions	interaction	NNS	O
consisting	consist	VBG	O
of	of	IN	O
bond	bond	NN	O
,	,	,	O
angle	angle	NN	O
,	,	,	O
dihedral	dihedral	JJ	O
,	,	,	O
and	and	CC	O
improper	improper	JJ	O
interactions	interaction	NNS	O
.	.	.	O

The	the	DT	O
non	non	JJ	O
-	-	JJ	O
bonded	bonded	JJ	O
interactions	interaction	NNS	O
include	include	VBP	O
both	both	CC	O
electrostatic	electrostatic	JJ	O
and	and	CC	O
van	van	NNP	O
der	der	IN	O
Waals	Waals	NNP	O
interactions	interaction	NNS	O
and	and	CC	O
are	be	VBP	O
modelled	model	VBN	O
using	use	VBG	O
a	a	DT	O
Coulomb	Coulomb	NNP	O
and	and	CC	O
Lennard	Lennard	NNP	O
-	-	HYPH	O
Jones	Jones	NNP	O
potential	potential	JJ	O
function	function	NN	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
free	free	JJ	O
energy	energy	NN	O
of	of	IN	O
solvation	solvation	NN	O
is	be	VBZ	O
well	well	RB	O
defined	define	VBN	O
by	by	IN	O
the	the	DT	O
energy	energy	NN	O
required	require	VBN	O
to	to	TO	O
transfer	transfer	VB	O
a	a	DT	O
solute	solute	NN	O
from	from	IN	O
vacuum	vacuum	NN	O
into	into	IN	O
the	the	DT	O
solvent	solvent	NN	O
.	.	.	O

In	in	IN	O
the	the	DT	O
MMPBSA	MMPBSA	NNP	O
method	method	NN	O
,	,	,	O
it	-PRON-	PRP	O
is	be	VBZ	O
calculated	calculate	VBN	O
using	use	VBG	O
an	an	DT	O
implicit	implicit	JJ	O
solvent	solvent	NN	O
model	model	NN	O
.	.	.	O

The	the	DT	O
solvation	solvation	NN	O
free	free	JJ	O
energy	energy	NN	O
is	be	VBZ	O
defined	define	VBN	O
as	as	IN	O
:	:	:	O
Gsolvation	gsolvation	NN	O
=	=	SYM	O
Gpolar+Gnon	Gpolar+Gnon	NNP	O
-	-	HYPH	O
polar	polar	JJ	O
where	where	WRB	O
Gpolar	Gpolar	NNP	O
and	and	CC	O
Gnon	Gnon	NNP	O
-	-	HYPH	O
polar	polar	NNP	O
are	be	VBP	O
the	the	DT	O
electrostatic	electrostatic	JJ	O
and	and	CC	O
non	non	JJ	O
-	-	JJ	O
electrostatic	electrostatic	JJ	O
contributions	contribution	NNS	O
to	to	IN	O
the	the	DT	O
solvation	solvation	NN	O
free	free	JJ	O
energy	energy	NN	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

LBVS	LBVS	NNP	O
approach	approach	NN	O
was	be	VBD	O
employed	employ	VBN	O
to	to	TO	O
filter	filter	VB	O
compounds	compound	NNS	O
so	so	IN	O
as	as	IN	O
to	to	TO	O
build	build	VB	O
the	the	DT	O
SphK1	SphK1	NNP	O
inhibitor	inhibitor	NN	O
library	library	NN	O
.	.	.	O

The	the	DT	O
PF-543	PF-543	NNP	O
,	,	,	O
a	a	DT	O
potent	potent	JJ	O
inhibitor	inhibitor	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
was	be	VBD	O
used	use	VBN	O
as	as	IN	O
input	input	NN	O
molecule	molecule	VBP	O
to	to	TO	O
extract	extract	VB	O
small	small	JJ	O
molecules	molecule	NNS	O
similar	similar	JJ	O
to	to	IN	O
SphK1	sphk1	JJ	O
inhibitor	inhibitor	NN	O
from	from	IN	O
the	the	DT	O
constructed	construct	VBN	O
libraries	library	NNS	O
using	use	VBG	O
virtual	virtual	JJ	O
screening	screening	NN	O
strategies	strategy	NNS	O
.	.	.	O

LBVS	LBVS	NNP	O
identified	identify	VBD	O
20,800	20,800	CD	O
hits	hit	NNS	O
from	from	IN	O
various	various	JJ	O
molecular	molecular	JJ	O
and	and	CC	O
virtual	virtual	JJ	O
libraries	library	NNS	O
including	include	VBG	O
DrugBank	DrugBank	NNP	O
,	,	,	O
Ligand	Ligand	NNP	O
Expo	Expo	NNP	O
,	,	,	O
ChEMBL	ChEMBL	NNP	O
,	,	,	O
ChEBI	ChEBI	NNP	O
,	,	,	O
GLASS	GLASS	NNP	O
,	,	,	O
HMDB	HMDB	NNP	O
,	,	,	O
and	and	CC	O
ZINC	ZINC	NNP	O
databases	database	NNS	O
as	as	IN	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
1	1	CD	O
.	.	.	O

The	the	DT	O
flowchart	flowchart	NN	O
showing	show	VBG	O
the	the	DT	O
ligand	ligand	NN	O
-	-	HYPH	O
based	base	VBN	O
virtual	virtual	JJ	O
screening	screening	NN	O
of	of	IN	O
compounds	compound	NNS	O
.	.	.	O

All	all	DT	O
20,800	20,800	CD	O
compounds	compound	NNS	O
and	and	CC	O
PF-543	PF-543	NNP	O
were	be	VBD	O
subjected	subject	VBN	O
to	to	IN	O
drug	drug	NN	O
likeness	likeness	NN	O
,	,	,	O
lead	lead	JJ	O
likeness	likeness	NN	O
,	,	,	O
and	and	CC	O
PAINS	PAINS	NNP	O
analyses	analysis	NNS	O
.	.	.	O

We	-PRON-	PRP	O
have	have	VBP	O
identified	identify	VBN	O
621	621	CD	O
hits	hit	NNS	O
that	that	WDT	O
obeyed	obey	VBD	O
all	all	PDT	O
the	the	DT	O
parameters	parameter	NNS	O
of	of	IN	O
drug	drug	NN	O
likeness	likeness	NN	O
,	,	,	O
lead	lead	JJ	O
likeness	likeness	NN	O
,	,	,	O
and	and	CC	O
PAINS	PAINS	NNP	O
analyses	analysis	NNS	O
,	,	,	O
but	but	CC	O
the	the	DT	O
drug	drug	NN	O
PF-543	PF-543	NNP	O
failed	fail	VBD	O
at	at	IN	O
two	two	CD	O
parameters	parameter	NNS	O
,	,	,	O
namely	namely	RB	O
ghose	ghose	JJ	O
filtration	filtration	NN	O
and	and	CC	O
lead	lead	JJ	O
likeness	likeness	NN	O
.	.	.	O

The	the	DT	O
result	result	NN	O
of	of	IN	O
top	top	JJ	O
10	10	CD	O
compounds	compound	NNS	O
and	and	CC	O
PF-543	PF-543	NNP	O
fulfilling	fulfil	VBG	O
the	the	DT	O
drug	drug	NN	O
likeness	likeness	NN	O
features	feature	NNS	O
is	be	VBZ	O
shown	show	VBN	O
in	in	IN	O
Table	table	NN	O
1	1	CD	O
.	.	.	O

Analysis	analysis	NN	O
of	of	IN	O
drug	drug	NN	O
like	like	IN	O
properties	property	NNS	O
of	of	IN	O
top	top	JJ	O
10	10	CD	O
compounds	compound	NNS	O
and	and	CC	O
PF-543	PF-543	NNP	O
on	on	IN	O
the	the	DT	O
basis	basis	NN	O
of	of	IN	O
Lipinskiâs	Lipinskiâs	NNP	O
RO5	RO5	NNP	O
.	.	.	O

The	the	DT	O
selected	select	VBN	O
compounds	compound	NNS	O
were	be	VBD	O
subjected	subject	VBN	O
to	to	IN	O
ADMET	ADMET	NNS	O
screening	screening	NN	O
which	which	WDT	O
includes	include	VBZ	O
in	in	IN	O
silico	silico	NNP	O
prediction	prediction	NN	O
of	of	IN	O
human	human	JJ	O
intestinal	intestinal	JJ	O
absorption	absorption	NN	O
,	,	,	O
and	and	CC	O
blood	blood	NN	O
brain	brain	NN	O
barrier	barrier	NN	O
parameters	parameter	NNS	O
of	of	IN	O
pharmacokinetics	pharmacokinetic	NNS	O
.	.	.	O

Out	out	IN	O
of	of	IN	O
621	621	CD	O
compounds	compound	NNS	O
,	,	,	O
only	only	RB	O
492	492	CD	O
followed	follow	VBD	O
the	the	DT	O
HIA	HIA	NNP	O
and	and	CC	O
BBB	BBB	NNP	O
criteria	criterion	NNS	O
.	.	.	O

The	the	DT	O
compounds	compound	NNS	O
which	which	WDT	O
show	show	VBP	O
HIA	HIA	NNP	O
levels	level	NNS	O
0	0	CD	O
,	,	,	O
1	1	CD	O
,	,	,	O
2	2	CD	O
,	,	,	O
and	and	CC	O
3	3	CD	O
reflect	reflect	VBP	O
excellent	excellent	JJ	O
,	,	,	O
mild	mild	JJ	O
,	,	,	O
low	low	JJ	O
,	,	,	O
and	and	CC	O
very	very	RB	O
low	low	JJ	O
absorption	absorption	NN	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
BBB	BBB	NNP	O
reflects	reflect	VBZ	O
penetration	penetration	NN	O
level	level	NN	O
to	to	TO	O
be	be	VB	O
very	very	RB	O
large	large	JJ	O
,	,	,	O
large	large	JJ	O
,	,	,	O
normal	normal	JJ	O
,	,	,	O
poor	poor	JJ	O
,	,	,	O
and	and	CC	O
limitless	limitless	NN	O
.	.	.	O

Further	further	RB	O
,	,	,	O
it	-PRON-	PRP	O
was	be	VBD	O
checked	check	VBN	O
for	for	IN	O
plasma	plasma	NN	O
protein	protein	NN	O
binding	bind	VBG	O
properties	property	NNS	O
of	of	IN	O
ADMET	ADMET	NNS	O
.	.	.	O

Subsequently	subsequently	RB	O
,	,	,	O
230	230	CD	O
compounds	compound	NNS	O
succeeded	succeed	VBN	O
after	after	IN	O
checking	check	VBG	O
on	on	IN	O
parameter	parameter	NN	O
of	of	IN	O
dissolvability	dissolvability	NN	O
.	.	.	O

Only	only	RB	O
55	55	CD	O
molecules	molecule	NNS	O
were	be	VBD	O
successfully	successfully	RB	O
depicted	depict	VBN	O
as	as	IN	O
non	non	JJ	O
-	-	JJ	O
carcinogenic	carcinogenic	JJ	O
.	.	.	O

Overall	overall	JJ	O
process	process	NN	O
of	of	IN	O
virtual	virtual	JJ	O
screening	screening	NN	O
is	be	VBZ	O
summarised	summarise	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
1	1	CD	O
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
aforementioned	aforementioned	JJ	O
compounds	compound	NNS	O
are	be	VBP	O
tested	test	VBN	O
for	for	IN	O
CYP2D6	CYP2D6	NNP	O
metabolism	metabolism	NN	O
in	in	IN	O
which	which	WDT	O
232	232	CD	O
compounds	compound	NNS	O
were	be	VBD	O
observed	observe	VBN	O
to	to	TO	O
be	be	VB	O
nonsuppressor	nonsuppressor	NN	O
of	of	IN	O
Cytochrome	Cytochrome	NNP	O
P4502D6	p4502d6	NN	O
showing	show	VBG	O
the	the	DT	O
Bayesian	bayesian	JJ	O
score	score	NN	O
of	of	IN	O
less	less	JJR	O
than	than	IN	O
0.162	0.162	CD	O
.	.	.	O

After	after	IN	O
ADMET	ADMET	NNP	O
analysis	analysis	NN	O
,	,	,	O
it	-PRON-	PRP	O
was	be	VBD	O
observed	observe	VBN	O
that	that	IN	O
all	all	PDT	O
the	the	DT	O
55	55	CD	O
compounds	compound	NNS	O
were	be	VBD	O
following	follow	VBG	O
all	all	PDT	O
the	the	DT	O
parameters	parameter	NNS	O
of	of	IN	O
ADMET	ADMET	NNP	O
.	.	.	O

This	this	DT	O
information	information	NN	O
unravelled	unravel	VBD	O
that	that	IN	O
these	these	DT	O
compounds	compound	NNS	O
have	have	VBP	O
excellent	excellent	JJ	O
absorption	absorption	NN	O
level	level	NN	O
.	.	.	O

Additionally	additionally	RB	O
,	,	,	O
10	10	CD	O
compounds	compound	NNS	O
have	have	VBP	O
high	high	JJ	O
penetration	penetration	NN	O
level	level	NN	O
and	and	CC	O
the	the	DT	O
remaining	remain	VBG	O
45	45	CD	O
compounds	compound	NNS	O
have	have	VBP	O
medium	medium	JJ	O
penetration	penetration	NN	O
level	level	NN	O
.	.	.	O

It	-PRON-	PRP	O
was	be	VBD	O
also	also	RB	O
discovered	discover	VBN	O
that	that	IN	O
all	all	PDT	O
the	the	DT	O
55	55	CD	O
compounds	compound	NNS	O
were	be	VBD	O
not	not	RB	O
bound	bind	VBN	O
to	to	IN	O
plasma	plasma	NN	O
proteins	protein	NNS	O
indicating	indicate	VBG	O
good	good	JJ	O
bioavailability	bioavailability	NN	O
.	.	.	O

Each	each	DT	O
of	of	IN	O
the	the	DT	O
55	55	CD	O
compounds	compound	NNS	O
were	be	VBD	O
observed	observe	VBN	O
to	to	TO	O
be	be	VB	O
noninhibitors	noninhibitor	NNS	O
of	of	IN	O
CYP2D6	CYP2D6	NNP	O
suggesting	suggest	VBG	O
that	that	IN	O
these	these	DT	O
can	can	MD	O
be	be	VB	O
utilised	utilise	VBN	O
in	in	IN	O
the	the	DT	O
liver	liver	NN	O
.	.	.	O

In	in	IN	O
the	the	DT	O
event	event	NN	O
of	of	IN	O
solubility	solubility	NN	O
level	level	NN	O
,	,	,	O
all	all	DT	O
55	55	CD	O
compounds	compound	NNS	O
were	be	VBD	O
following	follow	VBG	O
great	great	JJ	O
dissolvability	dissolvability	NN	O
levels	level	NNS	O
3	3	CD	O
and	and	CC	O
2	2	CD	O
.	.	.	O

With	with	IN	O
regard	regard	NN	O
to	to	IN	O
toxicity	toxicity	NN	O
,	,	,	O
all	all	DT	O
selected	select	VBN	O
compounds	compound	NNS	O
were	be	VBD	O
found	find	VBN	O
to	to	TO	O
be	be	VB	O
non	non	JJ	O
-	-	JJ	O
carcinogenic	carcinogenic	JJ	O
and	and	CC	O
non	non	JJ	O
-	-	JJ	O
mutagenic	mutagenic	JJ	O
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
ADMET	admet	JJ	O
analysis	analysis	NN	O
of	of	IN	O
PF-543	PF-543	NNP	O
was	be	VBD	O
found	find	VBN	O
comparable	comparable	JJ	O
to	to	IN	O
the	the	DT	O
predicted	predict	VBN	O
compounds	compound	NNS	O
.	.	.	O

ADMET	admet	JJ	O
analyses	analysis	NNS	O
of	of	IN	O
top	top	JJ	O
10	10	CD	O
compounds	compound	NNS	O
along	along	IN	O
with	with	IN	O
standard	standard	JJ	O
molecule	molecule	NN	O
PF-543	PF-543	NNP	O
are	be	VBP	O
shown	show	VBN	O
in	in	IN	O
Table	table	NN	O
2	2	CD	O
.	.	.	O

ADMET	admet	JJ	O
calculation	calculation	NN	O
of	of	IN	O
top	top	JJ	O
10	10	CD	O
compounds	compound	NNS	O
and	and	CC	O
PF-543	PF-543	NNP	O
.	.	.	O

In	in	IN	O
order	order	NN	O
to	to	TO	O
check	check	VB	O
the	the	DT	O
binding	bind	VBG	O
interaction	interaction	NN	O
of	of	IN	O
55	55	CD	O
ligands	ligand	NNS	O
with	with	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
molecular	molecular	JJ	O
docking	docking	NN	O
studies	study	NNS	O
was	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
using	use	VBG	O
AutoDock	AutoDock	NNP	O
tools	tool	NNS	O
.	.	.	O

The	the	DT	O
illustrated	illustrate	VBN	O
data	datum	NNS	O
uncovered	uncover	VBD	O
that	that	IN	O
ÎG	ÎG	NNP	O
values	value	NNS	O
of	of	IN	O
three	three	CD	O
compounds	compound	NNS	O
,	,	,	O
namely	namely	RB	O
ZINC06823429	ZINC06823429	NNP	O
,	,	,	O
ZINC95421501	zinc95421501	ADD	O
,	,	,	O
and	and	CC	O
ZINC95421070	ZINC95421070	NNP	O
were	be	VBD	O
observed	observe	VBN	O
to	to	TO	O
be	be	VB	O
higher	high	JJR	O
than	than	IN	O
the	the	DT	O
standard	standard	JJ	O
drug	drug	NN	O
PF-543	PF-543	NNP	O
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
ZINC06823429	ZINC06823429	NNP	O
was	be	VBD	O
found	find	VBN	O
to	to	TO	O
have	have	VB	O
greater	great	JJR	O
binding	bind	VBG	O
energy	energy	NN	O
â11.36âkcal	â11.36âkcal	JJ	O
/	/	SYM	O
mol	mol	NN	O
as	as	IN	O
compared	compare	VBN	O
with	with	IN	O
other	other	JJ	O
drugs	drug	NNS	O
including	include	VBG	O
PF-543	PF-543	NNP	O
â9.90âkcal	â9.90âkcal	NNP	O
/	/	SYM	O
mol	mol	NN	O
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
it	-PRON-	PRP	O
is	be	VBZ	O
of	of	IN	O
great	great	JJ	O
importance	importance	NN	O
that	that	IN	O
the	the	DT	O
predicted	predict	VBN	O
compound	compound	NN	O
namely	namely	RB	O
ZINC06823429	ZINC06823429	NNP	O
might	may	MD	O
be	be	VB	O
used	use	VBN	O
as	as	IN	O
potent	potent	JJ	O
inhibitor	inhibitor	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
.	.	.	O

The	the	DT	O
docking	docking	NN	O
results	result	NNS	O
of	of	IN	O
top	top	JJ	O
10	10	CD	O
compounds	compound	NNS	O
and	and	CC	O
standard	standard	JJ	O
PF-543	PF-543	NNP	O
is	be	VBZ	O
summarised	summarise	VBN	O
in	in	IN	O
Table	table	NN	O
3	3	CD	O
.	.	.	O

Docking	dock	VBG	O
analysis	analysis	NN	O
of	of	IN	O
top	top	JJ	O
10	10	CD	O
compounds	compound	NNS	O
and	and	CC	O
comparison	comparison	NN	O
with	with	IN	O
known	know	VBN	O
drug	drug	NN	O
.	.	.	O

Calculated	calculate	VBN	O
free	free	JJ	O
energy	energy	NN	O
of	of	IN	O
binding	binding	NN	O
ÎG	îg	FW	O
in	in	IN	O
kcal	kcal	JJ	O
/	/	SYM	O
mol	mol	NN	O
.	.	.	O

Calculated	calculated	JJ	O
inhibition	inhibition	NN	O
constant	constant	JJ	O
Ki	Ki	NNP	O
from	from	IN	O
AutoDock	AutoDock	NNP	O
Tools	Tools	NNP	O
4.2	4.2	CD	O
.	.	.	O

The	the	DT	O
binding	bind	VBG	O
mode	mode	NN	O
of	of	IN	O
ZINC06823429	ZINC06823429	NNP	O
with	with	IN	O
the	the	DT	O
SphK1	SphK1	NNP	O
.	.	.	O

The	the	DT	O
overall	overall	JJ	O
structure	structure	NN	O
of	of	IN	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
complex	complex	JJ	O
showing	show	VBG	O
protein	protein	NN	O
in	in	IN	O
cartoon	cartoon	NN	O
model	model	NN	O
and	and	CC	O
ligand	ligand	NN	O
in	in	IN	O
stick	stick	NN	O
.	.	.	O

Interaction	Interaction	NNP	O
of	of	IN	O
ZINC06823429	ZINC06823429	NNP	O
to	to	IN	O
the	the	DT	O
SphK1	SphK1	NNP	O
residues	residue	NNS	O
.	.	.	O

2D	2D	VBN	O
diagram	diagram	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
interaction	interaction	NN	O
with	with	IN	O
the	the	DT	O
compound	compound	NN	O
ZINC06823429	ZINC06823429	NNP	O
.	.	.	O

The	the	DT	O
active	active	JJ	O
site	site	NN	O
residues	residue	NNS	O
of	of	IN	O
SphK1	SphK1	NNP	O
interacting	interact	VBG	O
with	with	IN	O
ligand	ligand	NNP	O
ZINC06823429	ZINC06823429	NNP	O
by	by	IN	O
four	four	CD	O
conventional	conventional	JJ	O
H	h	NN	O
-	-	NN	O
bonds	bond	NNS	O
.	.	.	O

The	the	DT	O
binding	bind	VBG	O
mode	mode	NN	O
of	of	IN	O
ZINC95421501	ZINC95421501	NNP	O
with	with	IN	O
the	the	DT	O
SphK1	SphK1	NNP	O
.	.	.	O

The	the	DT	O
overall	overall	JJ	O
structure	structure	NN	O
of	of	IN	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
complex	complex	JJ	O
showing	show	VBG	O
protein	protein	NN	O
in	in	IN	O
cartoon	cartoon	NN	O
model	model	NN	O
and	and	CC	O
ligand	ligand	NN	O
in	in	IN	O
stick	stick	NN	O
.	.	.	O

Interaction	Interaction	NNP	O
of	of	IN	O
ZINC95421501	ZINC95421501	NNP	O
to	to	IN	O
the	the	DT	O
SphK1	SphK1	NNP	O
residues	residue	NNS	O
.	.	.	O

2D	2D	VBN	O
diagram	diagram	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
interaction	interaction	NN	O
with	with	IN	O
the	the	DT	O
compound	compound	NN	O
ZINC95421501	zinc95421501	ADD	O
.	.	.	O

The	the	DT	O
active	active	JJ	O
site	site	NN	O
residues	residue	NNS	O
of	of	IN	O
SphK1	SphK1	NNP	O
interacting	interact	VBG	O
with	with	IN	O
ligand	ligand	NNP	O
ZINC95421501	ZINC95421501	NNP	O
by	by	IN	O
two	two	CD	O
conventional	conventional	JJ	O
H	h	NN	O
-	-	NN	O
bonds	bond	NNS	O
.	.	.	O

The	the	DT	O
binding	bind	VBG	O
mode	mode	NN	O
of	of	IN	O
ZINC95421070	ZINC95421070	NFP	O
with	with	IN	O
the	the	DT	O
SphK1	SphK1	NNP	O
.	.	.	O

The	the	DT	O
overall	overall	JJ	O
structure	structure	NN	O
of	of	IN	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
complex	complex	JJ	O
showing	show	VBG	O
protein	protein	NN	O
in	in	IN	O
cartoon	cartoon	NN	O
model	model	NN	O
and	and	CC	O
ligand	ligand	NN	O
in	in	IN	O
stick	stick	NN	O
.	.	.	O

Interaction	Interaction	NNP	O
of	of	IN	O
ZINC95421070	ZINC95421070	NNP	O
to	to	IN	O
the	the	DT	O
SphK1	SphK1	NNP	O
residues	residue	NNS	O
.	.	.	O

2D	2D	VBN	O
diagram	diagram	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
interaction	interaction	NN	O
with	with	IN	O
the	the	DT	O
compound	compound	NN	O
ZINC95421070	ZINC95421070	NFP	O
.	.	.	O

The	the	DT	O
active	active	JJ	O
site	site	NN	O
residues	residue	NNS	O
of	of	IN	O
SphK1	SphK1	NNP	O
interacting	interact	VBG	O
with	with	IN	O
ligand	ligand	NN	O
ZINC95421070	ZINC95421070	NNP	O
by	by	IN	O
three	three	CD	O
conventional	conventional	JJ	O
H	h	NN	O
-	-	HYPH	O
bonds	bond	NNS	O
.	.	.	O

The	the	DT	O
binding	bind	VBG	O
mode	mode	NN	O
of	of	IN	O
PF-543	PF-543	NNP	O
with	with	IN	O
the	the	DT	O
SphK1	SphK1	NNP	O
.	.	.	O

The	the	DT	O
overall	overall	JJ	O
structure	structure	NN	O
of	of	IN	O
SphK1âPF-543	sphk1âpf-543	JJ	O
complex	complex	JJ	O
showing	show	VBG	O
protein	protein	NN	O
in	in	IN	O
cartoon	cartoon	NN	O
model	model	NN	O
and	and	CC	O
ligand	ligand	NN	O
in	in	IN	O
stick	stick	NN	O
.	.	.	O

Interaction	Interaction	NNP	O
of	of	IN	O
PF-543	PF-543	NNP	O
to	to	IN	O
the	the	DT	O
SphK1	SphK1	NNP	O
residues	residue	NNS	O
.	.	.	O

2D	2D	VBN	O
diagram	diagram	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
interaction	interaction	NN	O
with	with	IN	O
the	the	DT	O
compound	compound	NN	O
PF-543	PF-543	NNP	O
.	.	.	O

The	the	DT	O
active	active	JJ	O
site	site	NN	O
residues	residue	NNS	O
of	of	IN	O
SphK1	SphK1	NNP	O
interacting	interact	VBG	O
with	with	IN	O
ligand	ligand	NN	O
PF-543	PF-543	NNP	O
by	by	IN	O
one	one	CD	O
conventional	conventional	JJ	O
H	h	NN	O
-	-	NN	O
bonds	bond	NNS	O
.	.	.	O

The	the	DT	O
average	average	JJ	O
potential	potential	JJ	O
energy	energy	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
SphK1âPF-543	SphK1âPF-543	NNP	O
,	,	,	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
,	,	,	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
,	,	,	O
and	and	CC	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
was	be	VBD	O
checked	check	VBN	O
prior	prior	RB	O
to	to	IN	O
MD	MD	NNP	O
simulations	simulation	NNS	O
to	to	TO	O
determine	determine	VB	O
the	the	DT	O
stability	stability	NN	O
of	of	IN	O
the	the	DT	O
systems	system	NNS	O
.	.	.	O

The	the	DT	O
constant	constant	JJ	O
fluctuations	fluctuation	NNS	O
of	of	IN	O
temperature	temperature	NN	O
at	at	IN	O
300Â	300â	CD	O
K	k	NN	O
for	for	IN	O
every	every	DT	O
system	system	NN	O
recommended	recommend	VBD	O
a	a	DT	O
stable	stable	JJ	O
and	and	CC	O
accurate	accurate	JJ	O
nature	nature	NN	O
of	of	IN	O
MD	MD	NNP	O
simulations	simulation	NNS	O
performed	perform	VBN	O
.	.	.	O

An	an	DT	O
average	average	JJ	O
potential	potential	JJ	O
energy	energy	NN	O
for	for	IN	O
aforesaid	aforesaid	JJ	O
system	system	NN	O
was	be	VBD	O
observed	observe	VBN	O
to	to	TO	O
be	be	VB	O
â767,455âkJ	â767,455âkJ	NNP	O
/	/	SYM	O
mol	mol	NN	O
,	,	,	O
766,868âkJ	766,868âkJ	NNP	O
/	/	SYM	O
mol	mol	NN	O
,	,	,	O
766,795âkJ	766,795âkJ	NNP	O
/	/	SYM	O
mol	mol	NN	O
,	,	,	O
767,127âkJ	767,127âkJ	NNP	O
/	/	SYM	O
mol	mol	NN	O
,	,	,	O
and	and	CC	O
766,972âkJ	766,972âkJ	NNP	O
/	/	SYM	O
mol	mol	NN	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
potential	potential	JJ	O
energy	energy	NN	O
for	for	IN	O
all	all	PDT	O
the	the	DT	O
system	system	NN	O
was	be	VBD	O
observed	observe	VBN	O
to	to	TO	O
be	be	VB	O
equivalent	equivalent	JJ	O
during	during	IN	O
the	the	DT	O
entire	entire	JJ	O
100âns	100âns	CD	O
MD	MD	NNP	O
process	process	NN	O
.	.	.	O

The	the	DT	O
average	average	JJ	O
potential	potential	JJ	O
energy	energy	NN	O
of	of	IN	O
all	all	PDT	O
the	the	DT	O
selected	select	VBN	O
complexes	complex	NNS	O
is	be	VBZ	O
shown	show	VBN	O
in	in	IN	O
Table	table	NN	O
4	4	CD	O
.	.	.	O

Calculated	calculated	JJ	O
parameters	parameter	NNS	O
for	for	IN	O
all	all	PDT	O
the	the	DT	O
systems	system	NNS	O
obtained	obtain	VBN	O
after	after	IN	O
100âns	100âns	CD	O
MD	MD	NNP	O
simulations	simulation	NNS	O
.	.	.	O

Protein	protein	NN	O
conformational	conformational	JJ	O
changes	change	NNS	O
are	be	VBP	O
due	due	JJ	O
to	to	IN	O
the	the	DT	O
binding	binding	NN	O
of	of	IN	O
ligand	ligand	NN	O
in	in	IN	O
the	the	DT	O
active	active	JJ	O
site	site	NN	O
of	of	IN	O
the	the	DT	O
protein	protein	NN	B
.	.	.	O

Root	root	NN	O
mean	mean	VBP	O
square	square	JJ	O
deviation	deviation	NN	O
is	be	VBZ	O
one	one	CD	O
of	of	IN	O
the	the	DT	O
vital	vital	JJ	O
parameter	parameter	NN	O
to	to	TO	O
determine	determine	VB	O
whether	whether	IN	O
the	the	DT	O
protein	protein	NN	O
is	be	VBZ	O
stable	stable	JJ	O
and	and	CC	O
close	close	JJ	O
to	to	IN	O
the	the	DT	O
experimental	experimental	JJ	O
structure	structure	NN	B
.	.	.	O

The	the	DT	O
average	average	JJ	O
RMSD	rmsd	JJ	O
values	value	NNS	O
were	be	VBD	O
observed	observe	VBN	O
to	to	TO	O
be	be	VB	O
0.29ânm	0.29ânm	NNP	O
,	,	,	O
0.44ânm	0.44ânm	NNP	O
,	,	,	O
0.34ânm	0.34ânm	NNP	O
,	,	,	O
0.25ânm	0.25ânm	NNP	O
,	,	,	O
and	and	CC	O
0.27ânm	0.27ânm	NNP	O
for	for	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
SphK1âPF-543	SphK1âPF-543	NNP	O
,	,	,	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
,	,	,	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
,	,	,	O
and	and	CC	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
RMSD	RMSD	NNP	O
plot	plot	NN	O
suggested	suggest	VBD	O
that	that	IN	O
the	the	DT	O
binding	binding	NN	O
of	of	IN	O
PF-543	PF-543	NNP	O
to	to	IN	O
the	the	DT	O
SphK1	sphk1	NN	O
leads	lead	VBZ	O
to	to	IN	O
high	high	JJ	O
structural	structural	JJ	O
deviations	deviation	NNS	O
from	from	IN	O
0.29ânm	0.29ânm	NNP	O
to	to	IN	O
0.44ânm	0.44ânm	NNP	O
.	.	.	O

Likewise	likewise	RB	O
,	,	,	O
the	the	DT	O
structural	structural	JJ	O
deviations	deviation	NNS	O
from	from	IN	O
0.29ânm	0.29ânm	NNP	O
to	to	IN	O
0.34ânm	0.34ânm	NNP	O
were	be	VBD	O
also	also	RB	O
reported	report	VBN	O
in	in	IN	O
case	case	NN	O
of	of	IN	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
Figure	Figure	NNP	O
6	6	CD	O
.	.	.	O

Accordingly	accordingly	RB	O
,	,	,	O
the	the	DT	O
binding	binding	NN	O
of	of	IN	O
ligands	ligand	NNS	O
such	such	JJ	O
as	as	IN	O
ZINC95421070	ZINC95421070	NNP	O
and	and	CC	O
ZINC95421501	ZINC95421501	NNP	O
leads	lead	VBZ	O
to	to	TO	O
decrease	decrease	VB	O
in	in	IN	O
the	the	DT	O
RMSD	rmsd	JJ	O
values	value	NNS	O
of	of	IN	O
SphK1	SphK1	NNP	O
.	.	.	O

The	the	DT	O
RMSD	RMSD	NNP	O
plot	plot	NN	O
suggested	suggest	VBD	O
that	that	IN	O
inhibition	inhibition	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
leads	lead	VBZ	O
to	to	IN	O
large	large	JJ	O
structural	structural	JJ	O
deviations	deviation	NNS	O
,	,	,	O
and	and	CC	O
ligands	ligand	VBZ	O
PF-543	PF-543	NNP	O
and	and	CC	O
ZINC06823429	ZINC06823429	NNP	O
were	be	VBD	O
reported	report	VBN	O
to	to	TO	O
have	have	VB	O
maximum	maximum	JJ	O
inhibition	inhibition	NN	O
of	of	IN	O
the	the	DT	O
SphK1	SphK1	NNP	O
.	.	.	O

The	the	DT	O
orientations	orientation	NNS	O
of	of	IN	O
PF-543	PF-543	NNP	O
,	,	,	O
ZINC06823429	ZINC06823429	NNP	O
,	,	,	O
ZINC95421070	zinc95421070	ADD	O
,	,	,	O
and	and	CC	O
ZINC95421501	ZINC95421501	NNP	O
were	be	VBD	O
also	also	RB	O
analysed	analyse	VBN	O
in	in	IN	O
the	the	DT	O
internal	internal	JJ	O
cavity	cavity	NN	O
of	of	IN	O
the	the	DT	O
SphK1	SphK1	NNP	O
Figure	Figure	NNP	O
6	6	CD	O
.	.	.	O

The	the	DT	O
PF-543	PF-543	NNP	O
indicated	indicate	VBD	O
maximum	maximum	JJ	O
RMSD	rmsd	JJ	O
value	value	NN	O
but	but	CC	O
found	find	VBD	O
to	to	TO	O
be	be	VB	O
equilibrated	equilibrate	VBN	O
in	in	IN	O
the	the	DT	O
active	active	JJ	O
pocket	pocket	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
.	.	.	O

The	the	DT	O
ligand	ligand	NN	O
ZINC06823429	zinc06823429	CD	O
showed	show	VBD	O
constant	constant	JJ	O
fluctuations	fluctuation	NNS	O
throughout	throughout	IN	O
the	the	DT	O
MD	MD	NNP	O
simulations	simulation	NNS	O
.	.	.	O

The	the	DT	O
ligand	ligand	NN	O
ZINC95421070	ZINC95421070	NNP	O
and	and	CC	O
ZINC95421501	ZINC95421501	NNP	O
showed	show	VBD	O
random	random	JJ	O
fluctuations	fluctuation	NNS	O
initially	initially	RB	O
,	,	,	O
but	but	CC	O
equilibrated	equilibrate	VBN	O
after	after	IN	O
60âns	60âns	CD	O
.	.	.	O

The	the	DT	O
RMSF	RMSF	NNS	O
of	of	IN	O
the	the	DT	O
protein	protein	NN	O
upon	upon	IN	O
ligand	ligand	NNP	O
binding	binding	NN	O
was	be	VBD	O
plotted	plot	VBN	O
as	as	IN	O
function	function	NN	O
of	of	IN	O
residue	residue	JJ	O
number	number	NN	O
to	to	TO	O
determine	determine	VB	O
the	the	DT	O
mean	mean	JJ	O
fluctuations	fluctuation	NNS	O
of	of	IN	O
all	all	DT	O
residues	residue	NNS	O
during	during	IN	O
the	the	DT	O
simulation	simulation	NN	O
Figure	Figure	NNP	O
6	6	CD	O
.	.	.	O

The	the	DT	O
graphical	graphical	JJ	O
representation	representation	NN	O
of	of	IN	O
RMSF	RMSF	NNP	O
demonstrated	demonstrate	VBD	O
that	that	IN	O
the	the	DT	O
fluctuations	fluctuation	NNS	O
in	in	IN	O
residues	residue	NNS	O
are	be	VBP	O
present	present	JJ	O
in	in	IN	O
SphK1	SphK1	NNP	O
at	at	IN	O
distinct	distinct	JJ	O
regions	region	NNS	O
due	due	JJ	O
to	to	IN	O
binding	bind	VBG	O
of	of	IN	O
these	these	DT	O
ligands	ligand	NNS	O
.	.	.	O

The	the	DT	O
binding	binding	NN	O
of	of	IN	O
PF-543	PF-543	NNP	O
leads	lead	VBZ	O
to	to	TO	O
decrease	decrease	VB	O
in	in	IN	O
residual	residual	JJ	O
fluctuation	fluctuation	NN	O
at	at	IN	O
270â280	270â280	CD	O
aa	aa	NNP	O
,	,	,	O
300â350	300â350	CD	O
aa	aa	NNP	O
,	,	,	O
and	and	CC	O
370â400	370â400	CD	O
aa	aa	NNP	O
regions	region	NNS	O
.	.	.	O

The	the	DT	O
binding	binding	NN	O
of	of	IN	O
ZINC06823429	zinc06823429	CD	O
leads	lead	VBZ	O
to	to	TO	O
slightly	slightly	RB	O
increase	increase	VB	O
in	in	IN	O
residual	residual	JJ	O
fluctuations	fluctuation	NNS	O
throughout	throughout	IN	O
the	the	DT	O
100âns	100âns	CD	O
MD	MD	NNP	O
simulations	simulation	NNS	O
.	.	.	O

Accordingly	accordingly	RB	O
,	,	,	O
the	the	DT	O
binding	binding	NN	O
of	of	IN	O
ZINC95421070	ZINC95421070	NNP	O
and	and	CC	O
ZINC95421501	ZINC95421501	NNP	O
decreases	decrease	VBZ	O
the	the	DT	O
residual	residual	JJ	O
fluctuations	fluctuation	NNS	O
of	of	IN	O
SphK1	SphK1	NNP	O
.	.	.	O

These	these	DT	O
all	all	DT	O
selected	select	VBN	O
ligands	ligand	NNS	O
showed	show	VBD	O
different	different	JJ	O
impact	impact	NN	O
on	on	IN	O
SphK1	SphK1	NNP	O
.	.	.	O

Dynamics	dynamic	NNS	O
of	of	IN	O
ligands	ligand	NNS	O
binding	bind	VBG	O
to	to	IN	O
the	the	DT	O
SphK1	SphK1	NNP	O
.	.	.	O

RMSD	RMSD	NNP	O
plot	plot	NN	O
as	as	IN	O
a	a	DT	O
function	function	NN	O
of	of	IN	O
time	time	NN	O
.	.	.	O

Black	black	JJ	O
,	,	,	O
red	red	JJ	O
,	,	,	O
green	green	JJ	O
,	,	,	O
blue	blue	JJ	O
,	,	,	O
and	and	CC	O
yellow	yellow	JJ	O
colours	colour	NNS	O
represent	represent	VBP	O
values	value	NNS	O
obtained	obtain	VBN	O
for	for	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
SphK1âSTD	sphk1âstd	FW	O
,	,	,	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
,	,	,	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
,	,	,	O
and	and	CC	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

Comparison	comparison	NN	O
of	of	IN	O
orientations	orientation	NNS	O
of	of	IN	O
PF-543	PF-543	NNP	O
,	,	,	O
ZINC06823429	ZINC06823429	NNP	O
,	,	,	O
ZINC95421070	zinc95421070	ADD	O
,	,	,	O
and	and	CC	O
ZINC95421501	ZINC95421501	NFP	O
into	into	IN	O
the	the	DT	O
active	active	JJ	O
pocket	pocket	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
.	.	.	O

Backbone	backbone	NN	O
atomic	atomic	JJ	O
fluctuations	fluctuation	NNS	O
plot	plot	NN	O
for	for	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
SphK1âPF-543	SphK1âPF-543	NNP	O
,	,	,	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
,	,	,	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
,	,	,	O
and	and	CC	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
.	.	.	O

Time	Time	NNP	O
evolution	evolution	NN	O
of	of	IN	O
radius	radius	NN	O
of	of	IN	O
gyration	gyration	NN	O
values	value	NNS	O
during	during	IN	O
100,000âps	100,000âps	NNP	O
100âns	100âns	CD	O
of	of	IN	O
MD	MD	NNP	O
simulation	simulation	NN	O
.	.	.	O

The	the	DT	O
Rg	Rg	NNP	O
plot	plot	NN	O
for	for	IN	O
SphK1	SphK1	NNP	O
is	be	VBZ	O
shown	show	VBN	O
in	in	IN	O
black	black	NN	O
.	.	.	O

Red	red	JJ	O
,	,	,	O
green	green	JJ	O
,	,	,	O
blue	blue	JJ	O
,	,	,	O
and	and	CC	O
yellow	yellow	JJ	O
colours	colour	NNS	O
represent	represent	VBP	O
Rg	Rg	NNP	O
plot	plot	NN	O
for	for	IN	O
SphK1âPF-543	SphK1âPF-543	NNP	O
,	,	,	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
,	,	,	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
,	,	,	O
and	and	CC	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

Radius	radius	NN	O
of	of	IN	O
gyration	gyration	NN	O
determines	determine	VBZ	O
the	the	DT	O
stability	stability	NN	O
of	of	IN	O
protein	protein	NN	O
in	in	IN	O
a	a	DT	O
biological	biological	JJ	O
system	system	NN	O
and	and	CC	O
is	be	VBZ	O
connected	connect	VBN	O
to	to	IN	O
compactness	compactness	NN	O
of	of	IN	O
the	the	DT	O
protein	protein	NN	O
.	.	.	O

Due	due	IN	O
to	to	IN	O
less	less	RBR	O
compact	compact	JJ	O
packing	packing	NN	O
,	,	,	O
the	the	DT	O
radius	radius	NN	O
of	of	IN	O
gyration	gyration	NN	O
is	be	VBZ	O
supposed	suppose	VBN	O
to	to	TO	O
be	be	VB	O
higher	high	JJR	O
.	.	.	O

The	the	DT	O
average	average	JJ	O
Rg	Rg	NNP	O
values	value	NNS	O
for	for	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
SphK1âPF-543	SphK1âPF-543	NNP	O
,	,	,	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
,	,	,	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
,	,	,	O
and	and	CC	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
were	be	VBD	O
observed	observe	VBN	O
to	to	TO	O
be	be	VB	O
1.92ânm	1.92ânm	CD	O
,	,	,	O
1.96ânm	1.96ânm	NNP	O
,	,	,	O
1.93ânm	1.93ânm	NNP	O
,	,	,	O
1.90ânm	1.90ânm	CD	O
,	,	,	O
and	and	CC	O
1.92ânm	1.92ânm	NNP	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
average	average	JJ	O
Rg	Rg	NNP	O
values	value	NNS	O
of	of	IN	O
SphK1	SphK1	NNP	O
and	and	CC	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
were	be	VBD	O
found	find	VBN	O
to	to	TO	O
be	be	VB	O
equal	equal	JJ	O
.	.	.	O

The	the	DT	O
binding	binding	NN	O
of	of	IN	O
PF-543	PF-543	NNP	O
shows	show	VBZ	O
high	high	JJ	O
values	value	NNS	O
of	of	IN	O
Rg	Rg	NNP	O
of	of	IN	O
SphK1	SphK1	NNP	O
.	.	.	O

The	the	DT	O
binding	binding	NN	O
of	of	IN	O
ZINC06823429	zinc06823429	CD	O
initially	initially	RB	O
showed	show	VBD	O
the	the	DT	O
high	high	JJ	O
Rg	Rg	NNP	O
values	value	NNS	O
and	and	CC	O
thereafter	thereafter	RB	O
a	a	DT	O
sudden	sudden	JJ	O
decrease	decrease	NN	O
in	in	IN	O
Rg	Rg	NNP	O
values	value	NNS	O
was	be	VBD	O
reported	report	VBN	O
after	after	IN	O
50âns	50âns	CD	O
.	.	.	O

The	the	DT	O
lowest	low	JJS	O
Rg	Rg	NNP	O
values	value	NNS	O
were	be	VBD	O
reported	report	VBN	O
in	in	IN	O
case	case	NN	O
of	of	IN	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
Figure	Figure	NNP	O
6	6	CD	O
.	.	.	O

Solvent	solvent	NN	O
accessible	accessible	JJ	O
surface	surface	NN	O
area	area	NN	O
.	.	.	O

The	the	DT	O
solvent	solvent	NN	O
accessible	accessible	JJ	O
surface	surface	NN	O
area	area	NN	O
as	as	IN	O
a	a	DT	O
function	function	NN	O
of	of	IN	O
time	time	NN	O
.	.	.	O

Black	black	JJ	O
,	,	,	O
red	red	JJ	O
,	,	,	O
green	green	JJ	O
,	,	,	O
blue	blue	JJ	O
,	,	,	O
and	and	CC	O
yellow	yellow	JJ	O
colours	colour	NNS	O
represent	represent	VBP	O
values	value	NNS	O
obtained	obtain	VBN	O
for	for	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
SphK1âSTD	sphk1âstd	FW	O
,	,	,	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
,	,	,	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
,	,	,	O
and	and	CC	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
SASA	SASA	NNP	O
plot	plot	NN	O
was	be	VBD	O
further	further	RB	O
resolved	resolve	VBN	O
into	into	IN	O
hydrophobic	hydrophobic	NN	O
and	and	CC	O
hydrophilic	hydrophilic	JJ	O
surface	surface	NN	O
area	area	NN	O
for	for	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
SphK1âPF-543	SphK1âPF-543	NNP	O
,	,	,	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
,	,	,	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
,	,	,	O
and	and	CC	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
specificity	specificity	NN	O
of	of	IN	O
protein	protein	NNP	O
and	and	CC	O
ligand	ligand	NNP	O
interaction	interaction	NN	O
is	be	VBZ	O
governed	govern	VBN	O
by	by	IN	O
hydrogen	hydrogen	NN	O
bonding	bonding	NN	O
which	which	WDT	O
is	be	VBZ	O
a	a	DT	O
part	part	NN	O
of	of	IN	O
molecular	molecular	JJ	O
recognition	recognition	NN	B
.	.	.	O

To	to	TO	O
validate	validate	VB	O
the	the	DT	O
stability	stability	NN	O
of	of	IN	O
docked	dock	VBN	O
complexes	complex	NNS	O
,	,	,	O
the	the	DT	O
hydrogen	hydrogen	NN	O
bonds	bond	NNS	O
paired	pair	VBN	O
with	with	IN	O
0.35ânm	0.35ânm	NNP	O
amongst	amongst	IN	O
protein	protein	NN	O
and	and	CC	O
ligands	ligand	NNS	O
in	in	IN	O
SphK1âPF-543	SphK1âPF-543	NNP	O
,	,	,	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
,	,	,	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
,	,	,	O
and	and	CC	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
were	be	VBD	O
computed	compute	VBN	O
during	during	IN	O
the	the	DT	O
100âns	100âns	CD	O
MD	MD	NNP	O
simulations	simulation	NNS	O
.	.	.	O

It	-PRON-	PRP	O
has	have	VBZ	O
been	be	VBN	O
found	find	VBN	O
that	that	WDT	O
ligands	ligand	VBZ	O
such	such	JJ	O
as	as	IN	O
PF-543	PF-543	NNP	O
,	,	,	O
ZINC06823429	ZINC06823429	NNP	O
,	,	,	O
ZINC95421070	zinc95421070	ADD	O
,	,	,	O
and	and	CC	O
ZINC95421501	zinc95421501	CD	O
form	form	NN	O
maximum	maximum	JJ	O
2â3	2â3	NNP	O
,	,	,	O
6â7	6â7	CD	O
,	,	,	O
4â5	4â5	CD	O
,	,	,	O
and	and	CC	O
3â4	3â4	CD	O
hydrogen	hydrogen	NN	O
bonds	bond	NNS	O
with	with	IN	O
active	active	JJ	O
site	site	NN	O
residues	residue	NNS	O
of	of	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
ligand	ligand	NN	O
ZINC95421501	ZINC95421501	NNP	O
was	be	VBD	O
found	find	VBN	O
to	to	TO	O
have	have	VB	O
week	week	NN	O
interactions	interaction	NNS	O
during	during	IN	O
55â60âns	55â60âns	CD	O
time	time	NN	O
scale	scale	NN	O
.	.	.	O

The	the	DT	O
average	average	JJ	O
number	number	NN	O
of	of	IN	O
hydrogen	hydrogen	NN	O
bonds	bond	NNS	O
as	as	IN	O
a	a	DT	O
function	function	NN	O
of	of	IN	O
time	time	NN	O
.	.	.	O

Red	red	JJ	O
,	,	,	O
green	green	JJ	O
,	,	,	O
blue	blue	JJ	O
,	,	,	O
and	and	CC	O
yellow	yellow	JJ	O
colours	colour	NNS	O
represent	represent	VBP	O
the	the	DT	O
number	number	NN	O
of	of	IN	O
hydrogen	hydrogen	NN	O
bonds	bond	NNS	O
for	for	IN	O
SphK1âPF-543	SphK1âPF-543	NNP	O
,	,	,	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
,	,	,	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
,	,	,	O
and	and	CC	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
secondary	secondary	JJ	O
structure	structure	NN	O
components	component	NNS	O
such	such	JJ	O
as	as	IN	O
Î±-helix	Î±-helix	NNP	O
,	,	,	O
Î²-sheet	Î²-sheet	NNS	O
,	,	,	O
and	and	CC	O
loops	loop	NNS	O
were	be	VBD	O
categorised	categorise	VBN	O
and	and	CC	O
treated	treat	VBN	O
as	as	IN	O
individual	individual	JJ	O
components	component	NNS	O
for	for	IN	O
each	each	DT	O
time	time	NN	O
step	step	NN	O
.	.	.	O

The	the	DT	O
average	average	JJ	O
number	number	NN	O
of	of	IN	O
residues	residue	NNS	O
took	take	VBD	O
part	part	NN	O
in	in	IN	O
secondary	secondary	JJ	O
structure	structure	NN	O
formation	formation	NN	O
were	be	VBD	O
decreased	decrease	VBN	O
in	in	IN	O
all	all	DT	O
cases	case	NNS	O
.	.	.	O

The	the	DT	O
binding	binding	NN	O
of	of	IN	O
ligand	ligand	NNP	O
ZINC06823429	ZINC06823429	NNP	O
to	to	IN	O
the	the	DT	O
SphK1	SphK1	NNP	O
affects	affect	NNS	O
much	much	JJ	O
than	than	IN	O
other	other	JJ	O
ligands	ligand	NNS	O
.	.	.	O

It	-PRON-	PRP	O
may	may	MD	O
be	be	VB	O
due	due	IN	O
to	to	IN	O
proper	proper	JJ	O
inhibition	inhibition	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
or	or	CC	O
unfolding	unfold	VBG	O
in	in	IN	O
Î±-helical	î±-helical	JJ	O
regions	region	NNS	O
.	.	.	O

The	the	DT	O
Î²-sheets	î²-sheet	NNS	O
were	be	VBD	O
not	not	RB	O
affected	affect	VBN	O
much	much	RB	O
in	in	IN	O
case	case	NN	O
of	of	IN	O
SphK1âPF-543	SphK1âPF-543	NNP	O
and	and	CC	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
.	.	.	O

The	the	DT	O
structures	structure	NNS	O
of	of	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
SphK1âPF-543	SphK1âPF-543	NNP	O
,	,	,	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
,	,	,	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
,	,	,	O
and	and	CC	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
were	be	VBD	O
also	also	RB	O
extracted	extract	VBN	O
during	during	IN	O
the	the	DT	O
100âns	100âns	CD	O
MD	MD	NNP	O
simulations	simulation	NNS	O
to	to	TO	O
check	check	VB	O
the	the	DT	O
position	position	NN	O
of	of	IN	O
ligands	ligand	NNS	O
.	.	.	O

The	the	DT	O
docked	docked	JJ	O
ligands	ligand	NNS	O
occupied	occupy	VBD	O
the	the	DT	O
internal	internal	JJ	O
pocket	pocket	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
during	during	IN	O
the	the	DT	O
100âns	100âns	CD	O
time	time	NN	O
scale	scale	NN	O
.	.	.	O

The	the	DT	O
secondary	secondary	JJ	O
structure	structure	NN	O
plot	plot	NN	O
.	.	.	O

The	the	DT	O
graphical	graphical	JJ	O
representation	representation	NN	O
indicating	indicate	VBG	O
the	the	DT	O
structural	structural	JJ	O
elements	element	NNS	O
present	present	JJ	O
during	during	IN	O
100âns	100âns	CD	O
MD	MD	NNP	O
simulations	simulation	NNS	O
in	in	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
SphK1âPF-543	SphK1âPF-543	NNP	O
,	,	,	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
,	,	,	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
,	,	,	O
and	and	CC	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

Position	position	NN	O
of	of	IN	O
ligands	ligand	NNS	O
in	in	IN	O
the	the	DT	O
secondary	secondary	JJ	O
structure	structure	NN	O
framework	framework	NN	O
.	.	.	O

The	the	DT	O
secondary	secondary	JJ	O
structure	structure	NN	O
representation	representation	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
during	during	IN	O
100âns	100âns	CD	O
MD	MD	NNP	O
simulation	simulation	NN	O
in	in	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
SphK1âPF-543	SphK1âPF-543	NNP	O
,	,	,	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
,	,	,	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
,	,	,	O
and	and	CC	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

Percentage	percentage	NN	O
of	of	IN	O
residues	residue	NNS	O
participated	participate	VBD	O
in	in	IN	O
average	average	JJ	O
structure	structure	NN	O
formation	formation	NN	O
.	.	.	O

Structureâ=âÎ±-helixâ+âÎ²-sheetâ+âÎ²-bridgeâ+âturn	structureâ=âî±-helixâ+âî²-sheetâ+âî²-bridgeâ+âturn	UH	O
.	.	.	O

The	the	DT	O
principal	principal	JJ	O
component	component	NN	O
analysis	analysis	NN	O
reflects	reflect	VBZ	O
the	the	DT	O
total	total	JJ	O
expansion	expansion	NN	O
of	of	IN	O
a	a	DT	O
protein	protein	NN	O
during	during	IN	O
MD	MD	NNP	O
simulation	simulation	NN	B
.	.	.	O

The	the	DT	O
PCA	PCA	NNP	O
for	for	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
SphK1âPF-543	SphK1âPF-543	NNP	O
,	,	,	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
,	,	,	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
,	,	,	O
and	and	CC	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
was	be	VBD	O
calculated	calculate	VBN	O
.	.	.	O

In	in	IN	O
this	this	DT	O
method	method	NN	O
,	,	,	O
the	the	DT	O
dynamics	dynamic	NNS	O
of	of	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
SphK1âPF-543	SphK1âPF-543	NNP	O
,	,	,	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
,	,	,	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
,	,	,	O
and	and	CC	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
were	be	VBD	O
ascertained	ascertain	VBN	O
utilising	utilise	VBG	O
gmxcovar	gmxcovar	JJ	O
module	module	NN	O
with	with	IN	O
reference	reference	NN	O
to	to	IN	O
the	the	DT	O
backbone	backbone	NN	O
.	.	.	O

PCA	PCA	NNP	O
determines	determine	VBZ	O
the	the	DT	O
average	average	JJ	O
mobility	mobility	NN	O
of	of	IN	O
a	a	DT	O
protein	protein	NN	O
thus	thus	RB	O
revealing	reveal	VBG	O
the	the	DT	O
internal	internal	JJ	O
structures	structure	NNS	O
responsible	responsible	JJ	O
for	for	IN	O
atomic	atomic	JJ	O
fluctuations	fluctuation	NNS	B
.	.	.	O

The	the	DT	O
sum	sum	NN	O
of	of	IN	O
eigenvalues	eigenvalue	NNS	O
signifies	signify	VBZ	O
the	the	DT	O
total	total	JJ	O
mobility	mobility	NN	O
in	in	IN	O
the	the	DT	O
system	system	NN	O
.	.	.	O

It	-PRON-	PRP	O
can	can	MD	O
be	be	VB	O
utilised	utilise	VBN	O
to	to	TO	O
determine	determine	VB	O
the	the	DT	O
flexibility	flexibility	NN	O
of	of	IN	O
a	a	DT	O
protein	protein	NN	O
under	under	IN	O
distinct	distinct	JJ	O
conditions	condition	NNS	B
.	.	.	O

The	the	DT	O
trace	trace	NN	O
of	of	IN	O
the	the	DT	O
covariance	covariance	NN	O
matrix	matrix	NN	O
and	and	CC	O
eigenvalues	eigenvalue	NNS	O
was	be	VBD	O
found	find	VBN	O
to	to	TO	O
be	be	VB	O
313.94ânm2	313.94ânm2	CD	O
,	,	,	O
239.59ânm2	239.59ânm2	CD	O
,	,	,	O
341.45ânm2	341.45ânm2	CD	O
,	,	,	O
172.60ânm2	172.60ânm2	CD	O
,	,	,	O
and	and	CC	O
228.71ânm2	228.71ânm2	CD	O
for	for	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
SphK1âPF-543	SphK1âPF-543	NNP	O
,	,	,	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
,	,	,	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
,	,	,	O
and	and	CC	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
eigenvalues	eigenvalue	NNS	O
were	be	VBD	O
found	find	VBN	O
to	to	TO	O
be	be	VB	O
increased	increase	VBN	O
in	in	IN	O
case	case	NN	O
of	of	IN	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
clearly	clearly	RB	O
demonstrating	demonstrate	VBG	O
that	that	IN	O
the	the	DT	O
irregular	irregular	JJ	O
fluctuations	fluctuation	NNS	O
in	in	IN	O
SphK1	SphK1	NNP	O
increase	increase	NN	O
due	due	IN	O
to	to	IN	O
binding	bind	VBG	O
of	of	IN	O
ZINC06823429	zinc06823429	CD	O
.	.	.	O

Greater	great	JJR	O
eigenvalues	eigenvalue	NNS	O
reveal	reveal	VBP	O
greater	great	JJR	O
expansion	expansion	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
i.e.	i.e.	FW	O
low	low	JJ	O
compactness	compactness	NN	O
and	and	CC	O
possibly	possibly	RB	O
denaturation	denaturation	NN	O
.	.	.	O

The	the	DT	O
detailed	detailed	JJ	O
projections	projection	NNS	O
of	of	IN	O
eigenvectors	eigenvector	NNS	O
are	be	VBP	O
depicted	depict	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
12	12	CD	O
.	.	.	O

The	the	DT	O
gmx	gmx	NNP	O
anaeig	anaeig	NN	O
module	module	NN	O
reads	read	VBZ	O
a	a	DT	O
set	set	NN	O
of	of	IN	O
eigenvectors	eigenvector	NNS	O
and	and	CC	O
eigenvalues	eigenvalue	NNS	O
as	as	IN	O
input	input	NN	O
and	and	CC	O
returns	return	NNS	O
to	to	TO	O
project	project	VB	O
an	an	DT	O
MD	MD	NNP	O
trajectory	trajectory	NN	O
along	along	IN	O
a	a	DT	O
selected	select	VBN	O
eigenvector	eigenvector	NN	O
values	value	NNS	O
.	.	.	O

The	the	DT	O
atomic	atomic	JJ	O
fluctuations	fluctuation	NNS	O
during	during	IN	O
eigenvector	eigenvector	NN	O
calculation	calculation	NN	O
were	be	VBD	O
also	also	RB	O
reported	report	VBN	O
.	.	.	O

It	-PRON-	PRP	O
indicated	indicate	VBD	O
the	the	DT	O
random	random	JJ	O
fluctuations	fluctuation	NNS	O
in	in	IN	O
the	the	DT	O
atoms	atom	NNS	O
of	of	IN	O
SphK1	SphK1	NNP	O
upon	upon	IN	O
binding	bind	VBG	O
of	of	IN	O
different	different	JJ	O
ligands	ligand	NNS	O
.	.	.	O

The	the	DT	O
2D	2d	JJ	O
projection	projection	NN	O
of	of	IN	O
eigenvectors	eigenvector	NNS	O
indicated	indicate	VBD	O
diverse	diverse	JJ	O
protrusions	protrusion	NNS	O
of	of	IN	O
SphK1	SphK1	NNP	O
upon	upon	IN	O
binding	bind	VBG	O
with	with	IN	O
different	different	JJ	O
ligands	ligand	NNS	O
molecules	molecule	NNS	O
.	.	.	O

The	the	DT	O
outcomes	outcome	NNS	O
suggested	suggest	VBD	O
that	that	IN	O
the	the	DT	O
distinct	distinct	JJ	O
positions	position	NNS	O
of	of	IN	O
atoms	atom	NNS	O
are	be	VBP	O
due	due	JJ	O
to	to	IN	O
conformational	conformational	JJ	O
changes	change	NNS	O
in	in	IN	O
the	the	DT	O
SphK1.2D	SphK1.2D	NNP	O
projection	projection	NN	O
of	of	IN	O
trajectories	trajectory	NNS	O
.	.	.	O

The	the	DT	O
2D	2d	JJ	O
projections	projection	NNS	O
of	of	IN	O
trajectories	trajectory	NNS	O
on	on	IN	O
eigenvectors	eigenvector	NNS	O
showed	show	VBD	O
different	different	JJ	O
projections	projection	NNS	O
of	of	IN	O
SphK1	SphK1	NNP	O
in	in	IN	O
case	case	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
SphK1âPF-543	SphK1âPF-543	NNP	O
,	,	,	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
,	,	,	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
,	,	,	O
and	and	CC	O
SphK1âZINC95421501	SphK1âZINC95421501	NNP	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
binding	bind	VBG	O
energies	energy	NNS	O
were	be	VBD	O
calculated	calculate	VBN	O
by	by	IN	O
utilising	utilise	VBG	O
the	the	DT	O
polar	polar	JJ	O
and	and	CC	O
apolar	apolar	JJ	O
solvation	solvation	NN	O
criterion	criterion	NN	O
.	.	.	O

This	this	DT	O
investigation	investigation	NN	O
set	set	VBD	O
up	up	RP	O
the	the	DT	O
energies	energy	NNS	O
related	relate	VBN	O
with	with	IN	O
the	the	DT	O
binding	binding	NN	O
of	of	IN	O
PF-543	PF-543	NNP	O
,	,	,	O
ZINC06823429	ZINC06823429	NNP	O
,	,	,	O
ZINC95421070	zinc95421070	ADD	O
,	,	,	O
and	and	CC	O
ZINC95421501	zinc95421501	CD	O
to	to	IN	O
SphK1	SphK1	NNP	O
during	during	IN	O
the	the	DT	O
100âns	100âns	CD	O
MD	MD	NNP	O
simulations	simulation	NNS	O
.	.	.	O

The	the	DT	O
following	follow	VBG	O
proteinâligand	proteinâligand	NNP	O
energies	energy	NNS	O
have	have	VBP	O
been	be	VBN	O
computed	compute	VBN	O
such	such	JJ	O
as	as	IN	O
vdW	vdW	NNP	O
interaction	interaction	NN	O
energy	energy	NN	O
,	,	,	O
electrostatic	electrostatic	JJ	O
energy	energy	NN	O
,	,	,	O
polar	polar	JJ	O
solvation	solvation	NN	O
energy	energy	NN	O
,	,	,	O
SASA	SASA	NNP	O
energy	energy	NN	O
,	,	,	O
and	and	CC	O
average	average	JJ	O
binding	bind	VBG	O
energy	energy	NN	O
.	.	.	O

The	the	DT	O
polar	polar	JJ	O
energy	energy	NN	O
and	and	CC	O
apolar	apolar	JJ	O
energy	energy	NN	O
were	be	VBD	O
distinct	distinct	JJ	O
in	in	IN	O
different	different	JJ	O
cases	case	NNS	O
.	.	.	O

The	the	DT	O
proteinâligand	proteinâligand	NNP	O
vdW	vdW	NNP	O
energy	energy	NN	O
,	,	,	O
proteinâligand	proteinâligand	CC	O
electrostatic	electrostatic	JJ	O
energy	energy	NN	O
,	,	,	O
and	and	CC	O
proteinâligand	proteinâligand	IN	O
total	total	JJ	O
energy	energy	NN	O
were	be	VBD	O
found	find	VBN	O
to	to	TO	O
be	be	VB	O
lowest	low	JJS	O
in	in	IN	O
case	case	NN	O
of	of	IN	O
SphK1âZINC95421070	SphK1âZINC95421070	NNP	O
.	.	.	O

The	the	DT	O
final	final	JJ	O
average	average	JJ	O
binding	binding	NN	O
energy	energy	NN	O
calculations	calculation	NNS	O
also	also	RB	O
recommended	recommend	VBD	O
the	the	DT	O
week	week	NN	O
interaction	interaction	NN	O
of	of	IN	O
ZINC95421070	ZINC95421070	NNP	O
in	in	IN	O
the	the	DT	O
internal	internal	JJ	O
cavity	cavity	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
.	.	.	O

The	the	DT	O
ligands	ligand	NNS	O
ZINC06823429	ZINC06823429	NNP	O
and	and	CC	O
PF-543	PF-543	NNP	O
are	be	VBP	O
found	find	VBN	O
to	to	TO	O
have	have	VB	O
a	a	DT	O
good	good	JJ	O
binding	binding	JJ	O
energy	energy	NN	O
values	value	NNS	O
.	.	.	O

Average	average	JJ	O
binding	bind	VBG	O
energy	energy	NN	O
calculation	calculation	NN	O
using	use	VBG	O
g_mmpbsa	g_mmpbsa	NNP	O
package	package	NN	O
implemented	implement	VBN	O
in	in	IN	O
GROMACS	GROMACS	NNP	O
for	for	IN	O
high	high	JJ	O
-	-	HYPH	O
throughput	throughput	NN	O
MMPBSA	MMPBSA	NNP	O
calculation	calculation	NN	O
for	for	IN	O
proteinâligand	proteinâligand	NNP	O
complexes	complex	NNS	O
.	.	.	O

Breast	breast	NN	O
carcinoma	carcinoma	NN	O
continues	continue	VBZ	O
to	to	TO	O
be	be	VB	O
the	the	DT	O
worldâs	worldâs	CD	O
leading	lead	VBG	O
cause	cause	NN	O
of	of	IN	O
womenâs	womenâs	CD	O
death	death	NN	O
owing	owing	NN	O
to	to	IN	O
its	-PRON-	PRP$	O
poor	poor	JJ	O
prognosis	prognosis	NN	O
and	and	CC	O
recurrence	recurrence	NN	O
.	.	.	O

It	-PRON-	PRP	O
has	have	VBZ	O
been	be	VBN	O
observed	observe	VBN	O
that	that	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
a	a	DT	O
kinase	kinase	NN	O
that	that	WDT	O
generates	generate	VBZ	O
S1P	S1P	NNP	O
,	,	,	O
is	be	VBZ	O
highly	highly	RB	O
elevated	elevated	JJ	O
in	in	IN	O
multiple	multiple	JJ	O
carcinomas	carcinoma	NNS	O
including	include	VBG	O
breast	breast	NN	O
carcinoma	carcinoma	NN	B
.	.	.	O

The	the	DT	O
expression	expression	NN	O
level	level	NN	O
of	of	IN	O
SphK1	sphk1	NN	O
was	be	VBD	O
examined	examine	VBN	O
in	in	IN	O
feline	feline	JJ	O
mammary	mammary	JJ	O
tumour	tumour	NN	O
specimens	specimen	NNS	O
and	and	CC	O
found	find	VBD	O
that	that	IN	O
SphK1	SphK1	NNP	O
plays	play	VBZ	O
an	an	DT	O
important	important	JJ	O
role	role	NN	O
in	in	IN	O
feline	feline	JJ	O
mammary	mammary	JJ	O
tumours	tumour	NNS	O
and	and	CC	O
may	may	MD	O
be	be	VB	O
used	use	VBN	O
as	as	IN	O
therapeutic	therapeutic	JJ	O
target	target	NN	B
.	.	.	O

Targeting	target	VBG	O
SphK1	SphK1	NNP	O
in	in	IN	O
triple	triple	JJ	O
-	-	HYPH	O
negative	negative	JJ	O
MDA	MDA	NNP	O
-	-	HYPH	O
MB-231	MB-231	NNP	O
breast	breast	NN	O
cancer	cancer	NN	O
cells	cell	NNS	O
decreased	decrease	VBD	O
proliferation	proliferation	NN	O
and	and	CC	O
survival	survival	NN	O
by	by	IN	O
compromising	compromise	VBG	O
protein	protein	NN	O
kinase	kinase	NN	O
C	c	NN	O
activity	activity	NN	O
and	and	CC	O
cytokinesis	cytokinesis	NN	B
.	.	.	O

SphK1	sphk1	NN	O
activity	activity	NN	O
has	have	VBZ	O
also	also	RB	O
been	be	VBN	O
linked	link	VBN	O
to	to	IN	O
the	the	DT	O
effects	effect	NNS	O
of	of	IN	O
several	several	JJ	O
microRNAs	micrornas	NN	O
that	that	WDT	O
are	be	VBP	O
regulated	regulate	VBN	O
by	by	IN	O
oestrogen	oestrogen	NN	O
receptor	receptor	NN	O
.	.	.	O

The	the	DT	O
miR-515	mir-515	NN	O
-	-	HYPH	O
5P	5P	NNP	O
,	,	,	O
a	a	DT	O
tumour	tumour	NN	O
suppressor	suppressor	NN	O
shows	show	VBZ	O
to	to	TO	O
reduce	reduce	VB	O
SphK1	sphk1	JJ	O
activity	activity	NN	O
and	and	CC	O
loss	loss	NN	O
of	of	IN	O
miR-515	mir-515	NN	O
-	-	.	O
5P.	5p.	CD	O
In	in	IN	O
addition	addition	NN	O
,	,	,	O
17Î²-oestradiol	17î²-oestradiol	NN	O
treatment	treatment	NN	O
downregulated	downregulate	VBN	O
miR-515	mir-515	NN	O
-	-	HYPH	O
5P	5P	VBN	O
levels	level	NNS	O
in	in	IN	O
ER	ER	NNP	O
-	-	HYPH	O
positive	positive	JJ	O
compared	compare	VBN	O
to	to	IN	O
ER	ER	NNP	O
-	-	HYPH	O
negative	negative	JJ	O
breast	breast	NN	O
cancers	cancer	NNS	B
.	.	.	O

Recently	recently	RB	O
,	,	,	O
Costales	Costales	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	.	B
designed	design	VBD	O
a	a	DT	O
small	small	JJ	O
molecule	molecule	NN	O
that	that	WDT	O
selectively	selectively	RB	O
targets	target	VBZ	O
the	the	DT	O
microRNA-515	microRNA-515	NNPS	O
hairpin	hairpin	NNP	O
precursor	precursor	NN	O
to	to	TO	O
inhibit	inhibit	VB	O
the	the	DT	O
production	production	NN	O
of	of	IN	O
miR-515	mir-515	NN	O
that	that	WDT	O
represses	repress	VBZ	O
SphK1	sphk1	NN	O
enzyme	enzyme	NNS	O
.	.	.	O

Several	several	JJ	O
preclinical	preclinical	JJ	O
studies	study	NNS	O
have	have	VBP	O
used	use	VBN	O
mouse	mouse	NN	O
breast	breast	NN	O
cancer	cancer	NN	O
models	model	NNS	O
to	to	TO	O
investigate	investigate	VB	O
the	the	DT	O
effects	effect	NNS	O
of	of	IN	O
SphK1	SphK1	NNP	O
inhibitors	inhibitor	NNS	O
on	on	IN	O
tumour	tumour	NN	O
growth	growth	NN	O
.	.	.	O

A	a	DT	O
variety	variety	NN	O
of	of	IN	O
sphingolipid	sphingolipid	NNP	O
based	base	VBN	O
and	and	CC	O
nolipidic	nolipidic	JJ	O
small	small	JJ	O
molecule	molecule	JJ	O
inhibitors	inhibitor	NNS	O
of	of	IN	O
SphK1	SphK1	NNP	O
have	have	VBP	O
been	be	VBN	O
reported	report	VBN	O
and	and	CC	O
have	have	VBP	O
shown	show	VBN	O
cytotoxic	cytotoxic	JJ	O
effects	effect	NNS	O
in	in	IN	O
several	several	JJ	O
resistant	resistant	JJ	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	B
.	.	.	O

Many	many	JJ	O
of	of	IN	O
the	the	DT	O
inhibitors	inhibitor	NNS	O
are	be	VBP	O
withdrawn	withdraw	VBN	O
from	from	IN	O
clinical	clinical	JJ	O
trials	trial	NNS	O
due	due	IN	O
to	to	IN	O
their	-PRON-	PRP$	O
side	side	NN	O
effects	effect	NNS	O
and	and	CC	O
limited	limited	JJ	O
efficacy	efficacy	NN	O
.	.	.	O

A	a	DT	O
combination	combination	NN	O
of	of	IN	O
the	the	DT	O
non	non	JJ	O
-	-	JJ	O
specific	specific	JJ	O
SphK1	SphK1	NNP	O
inhibitor	inhibitor	NN	O
SKI	SKI	NNP	O
-	-	HYPH	O
II	II	NNP	O
with	with	IN	O
gefitinib	gefitinib	NNP	O
significantly	significantly	RB	O
inhibited	inhibit	VBN	O
growth	growth	NN	O
of	of	IN	O
xenograft	xenograft	NNP	O
MDA	MDA	NNP	O
-	-	HYPH	O
MB-468	MB-468	NNP	O
triple	triple	JJ	O
-	-	HYPH	O
negative	negative	JJ	O
breast	breast	NN	O
cancer	cancer	NN	O
tumours	tumour	NNS	O
,	,	,	O
whereas	whereas	IN	O
neither	neither	DT	O
SKI	SKI	NNP	O
-	-	HYPH	O
II	II	NNP	O
nor	nor	CC	O
gefitinib	gefitinib	NNP	O
alone	alone	RB	O
had	have	VBD	O
any	any	DT	O
effects	effect	NNS	B
.	.	.	O

Another	another	DT	O
SphK1	SphK1	NNP	O
inhibitor	inhibitor	NN	O
SKI-5C	SKI-5C	NNP	O
significantly	significantly	RB	O
reduced	reduce	VBD	O
the	the	DT	O
growth	growth	NN	O
of	of	IN	O
tumours	tumour	NNS	O
from	from	IN	O
TNBC	TNBC	NNP	O
cell	cell	NN	O
line	line	NN	O
MDA	MDA	NNP	O
-	-	HYPH	O
MB-231	MB-231	NNP	O
in	in	IN	O
xenografted	xenografte	VBN	O
SCID	SCID	NNP	O
mice	mouse	NNS	B
.	.	.	O

Recently	recently	RB	O
,	,	,	O
a	a	DT	O
series	series	NN	O
of	of	IN	O
amidine	amidine	NNP	O
-	-	HYPH	O
based	base	VBN	O
inhibitors	inhibitor	NNS	O
with	with	IN	O
high	high	JJ	O
selectivity	selectivity	NN	O
for	for	IN	O
SphK1	SphK1	NNP	O
were	be	VBD	O
predicted	predict	VBN	O
using	use	VBG	O
docking	docking	NN	O
study	study	NN	B
,	,	,	B
.	.	.	O

However	however	RB	O
,	,	,	O
these	these	DT	O
inhibitors	inhibitor	NNS	O
display	display	VBP	O
a	a	DT	O
short	short	JJ	O
half	half	JJ	O
-	-	HYPH	O
life	life	NN	O
.	.	.	O

A	a	DT	O
novel	novel	JJ	O
sphingosine	sphingosine	NN	O
competitive	competitive	JJ	O
inhibitor	inhibitor	NN	O
PF-543	PF-543	NNP	O
was	be	VBD	O
discovered	discover	VBN	O
and	and	CC	O
found	find	VBN	O
to	to	TO	O
inhibit	inhibit	VB	O
SphK1	SphK1	NNP	O
with	with	IN	O
an	an	DT	O
inhibitory	inhibitory	JJ	O
constant	constant	NN	O
of	of	IN	O
3.6ânM.	3.6ânm.	NN	O
In	in	IN	O
1483	1483	CD	O
head	head	NN	O
and	and	CC	O
neck	neck	NN	O
carcinoma	carcinoma	NN	O
cells	cell	NNS	O
,	,	,	O
which	which	WDT	O
are	be	VBP	O
characterised	characterise	VBN	O
by	by	IN	O
overexpression	overexpression	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
and	and	CC	O
high	high	JJ	O
rate	rate	NN	O
of	of	IN	O
S1P	s1p	NN	O
production	production	NN	O
,	,	,	O
PF-543	PF-543	NNP	O
decreased	decrease	VBD	O
the	the	DT	O
level	level	NN	O
of	of	IN	O
endogenous	endogenous	JJ	O
S1P	s1p	NN	B
.	.	.	O

In	in	IN	O
this	this	DT	O
regard	regard	NN	O
,	,	,	O
we	-PRON-	PRP	O
have	have	VBP	O
chosen	choose	VBN	O
PF-543	PF-543	NNP	O
as	as	IN	O
standard	standard	JJ	O
inhibitor	inhibitor	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
to	to	TO	O
compare	compare	VB	O
our	-PRON-	PRP$	O
findings	finding	NNS	O
.	.	.	O

Until	until	IN	O
now	now	RB	O
,	,	,	O
only	only	RB	O
few	few	JJ	O
inhibitors	inhibitor	NNS	O
are	be	VBP	O
known	know	VBN	O
to	to	TO	O
be	be	VB	O
effective	effective	JJ	O
in	in	IN	O
inhibition	inhibition	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
in	in	IN	O
breast	breast	NN	O
carcinoma	carcinoma	NN	O
but	but	CC	O
were	be	VBD	O
found	find	VBN	O
to	to	TO	O
have	have	VB	O
poor	poor	JJ	O
pharmacokinetics	pharmacokinetic	NNS	O
profile	profile	VB	O
,	,	,	O
cytotoxic	cytotoxic	NNP	O
at	at	IN	O
micro	micro	NNP	O
molar	molar	NNP	O
concentration	concentration	NN	O
and	and	CC	O
ineffective	ineffective	JJ	O
for	for	IN	O
persistent	persistent	JJ	O
survival	survival	NN	O
rate	rate	NN	O
in	in	IN	O
human	human	JJ	O
trials	trial	NNS	B
.	.	.	O

Hence	hence	RB	O
,	,	,	O
it	-PRON-	PRP	O
is	be	VBZ	O
required	require	VBN	O
to	to	TO	O
identify	identify	VB	O
more	more	RBR	O
influential	influential	JJ	O
inhibitors	inhibitor	NNS	O
that	that	WDT	O
selectively	selectively	RB	O
inhibit	inhibit	VB	O
SphK1	SphK1	NNP	O
and	and	CC	O
lead	lead	NN	O
to	to	IN	O
apoptosis	apoptosis	NN	O
and	and	CC	O
growth	growth	NN	O
arrest	arrest	NN	O
in	in	IN	O
breast	breast	NN	O
cancer	cancer	NN	O
cells	cell	NNS	O
without	without	IN	O
causing	cause	VBG	O
cytotoxic	cytotoxic	NN	O
impact	impact	NN	O
in	in	IN	O
healthy	healthy	JJ	O
cells	cell	NNS	O
.	.	.	O

The	the	DT	O
computational	computational	JJ	O
strategies	strategy	NNS	O
like	like	IN	O
virtual	virtual	JJ	O
screening	screening	NN	O
have	have	VBP	O
been	be	VBN	O
used	use	VBN	O
widely	widely	RB	O
as	as	IN	O
effective	effective	JJ	O
approaches	approach	NNS	O
in	in	IN	O
order	order	NN	O
to	to	TO	O
discover	discover	VB	O
and	and	CC	O
develop	develop	VB	O
new	new	JJ	O
compounds	compound	NNS	O
.	.	.	O

Previously	previously	RB	O
,	,	,	O
we	-PRON-	PRP	O
have	have	VBP	O
studied	study	VBN	O
structural	structural	JJ	O
and	and	CC	O
conformational	conformational	JJ	O
changes	change	NNS	O
in	in	IN	O
SphK1	SphK1	NNP	O
at	at	RB	O
different	different	JJ	O
pH	pH	NNP	O
using	use	VBG	O
various	various	JJ	O
spectroscopic	spectroscopic	JJ	O
techniques	technique	NNS	O
and	and	CC	O
computational	computational	JJ	O
methods	method	NNS	B
.	.	.	O

SphK1	sphk1	NN	O
maintains	maintain	VBZ	O
its	-PRON-	PRP$	O
secondary	secondary	JJ	O
and	and	CC	O
tertiary	tertiary	JJ	O
structure	structure	NN	O
in	in	IN	O
the	the	DT	O
pH	pH	NNP	O
range	range	NN	O
of	of	IN	O
7.5â10.0	7.5â10.0	CD	O
.	.	.	O

However	however	RB	O
,	,	,	O
protein	protein	NN	O
aggregation	aggregation	NN	O
was	be	VBD	O
observed	observe	VBN	O
in	in	IN	O
the	the	DT	O
acidic	acidic	JJ	O
pH	pH	NNP	O
range	range	NN	O
.	.	.	O

In	in	IN	O
the	the	DT	O
present	present	JJ	O
work	work	NN	O
,	,	,	O
we	-PRON-	PRP	O
have	have	VBP	O
identified	identify	VBN	O
a	a	DT	O
potent	potent	JJ	O
inhibitor	inhibitor	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
by	by	IN	O
using	use	VBG	O
several	several	JJ	O
computational	computational	JJ	O
approaches	approach	NNS	O
such	such	JJ	O
as	as	IN	O
LBVS	LBVS	NNP	O
,	,	,	O
molecular	molecular	JJ	O
docking	docking	NN	O
,	,	,	O
MD	MD	NNP	O
simulations	simulation	NNS	O
,	,	,	O
and	and	CC	O
the	the	DT	O
MMPBSA	MMPBSA	NNP	O
calculations	calculation	NNS	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
were	be	VBD	O
compared	compare	VBN	O
with	with	IN	O
a	a	DT	O
known	know	VBN	O
inhibitor	inhibitor	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
called	call	VBN	O
PF-543	PF-543	NNP	B
.	.	.	O

Our	-PRON-	PRP$	O
analysis	analysis	NN	O
suggested	suggest	VBD	O
that	that	IN	O
the	the	DT	O
LogP	LogP	NNP	O
value	value	NN	O
of	of	IN	O
ZINC06823429	ZINC06823429	NNP	O
is	be	VBZ	O
about	about	RB	O
3.39	3.39	CD	O
and	and	CC	O
that	that	IN	O
of	of	IN	O
PF543	PF543	NNP	O
is	be	VBZ	O
approximately	approximately	RB	O
5.89	5.89	CD	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

Thus	thus	RB	O
,	,	,	O
the	the	DT	O
probability	probability	NN	O
of	of	IN	O
ZINC06823429	zinc06823429	XX	O
being	be	VBG	O
well	well	RB	O
absorbed	absorb	VBN	O
is	be	VBZ	O
much	much	RB	O
better	well	JJR	O
as	as	IN	O
compared	compare	VBN	O
to	to	IN	O
PF-543	PF-543	NNP	O
.	.	.	O

The	the	DT	O
crystal	crystal	NN	O
structures	structure	NNS	O
of	of	IN	O
SphK1	SphK1	NNP	O
were	be	VBD	O
reported	report	VBN	O
in	in	IN	O
complex	complex	NN	O
with	with	IN	O
inhibitor	inhibitor	NN	O
PF-543	PF-543	NNP	O
,	,	,	O
that	that	DT	O
will	will	MD	O
aid	aid	VB	O
in	in	IN	O
the	the	DT	O
design	design	NN	O
of	of	IN	O
better	well	JJR	O
SphK1	sphk1	JJ	O
inhibitors	inhibitor	NNS	O
with	with	IN	O
improved	improve	VBN	O
properties	property	NNS	B
.	.	.	O

Additionally	additionally	RB	O
,	,	,	O
the	the	DT	O
ZINC06823429	ZINC06823429	NNP	O
followed	follow	VBD	O
all	all	PDT	O
the	the	DT	O
properties	property	NNS	O
of	of	IN	O
RO5	RO5	NNP	O
that	that	WDT	O
makes	make	VBZ	O
it	-PRON-	PRP	O
a	a	DT	O
drug	drug	NN	O
like	like	IN	O
molecule	molecule	VB	O
.	.	.	O

It	-PRON-	PRP	O
has	have	VBZ	O
same	same	JJ	O
number	number	NN	O
of	of	IN	O
hydrogen	hydrogen	NN	O
bond	bond	NN	O
donor	donor	NN	O
as	as	RB	O
well	well	RB	O
as	as	IN	O
hydrogen	hydrogen	NNP	O
bond	bond	NN	O
acceptor	acceptor	NN	O
when	when	WRB	O
compared	compare	VBN	O
with	with	IN	O
PF-543	PF-543	NNP	O
.	.	.	O

In	in	IN	O
accordance	accordance	NN	O
with	with	IN	O
the	the	DT	O
ADMET	ADMET	NNP	O
profiling	profiling	NN	O
,	,	,	O
the	the	DT	O
HIA	HIA	NNP	O
,	,	,	O
PPB	PPB	NNP	O
,	,	,	O
BBB	BBB	NNP	O
,	,	,	O
CYP2D6	CYP2D6	NNP	O
solubility	solubility	NN	O
,	,	,	O
and	and	CC	O
toxicity	toxicity	NN	O
value	value	NN	O
of	of	IN	O
ZINC06823429	ZINC06823429	NNP	O
was	be	VBD	O
found	find	VBN	O
to	to	TO	O
be	be	VB	O
in	in	IN	O
harmony	harmony	NN	O
with	with	IN	O
the	the	DT	O
standard	standard	JJ	O
drug	drug	NN	O
PF-543	PF-543	NNP	O
.	.	.	O

The	the	DT	O
molecular	molecular	JJ	O
docking	docking	NN	O
analysis	analysis	NN	O
suggested	suggest	VBD	O
that	that	IN	O
ZINC06823429	ZINC06823429	NNP	O
has	have	VBZ	O
higher	high	JJR	O
binding	bind	VBG	O
energy	energy	NN	O
â11.69âkcal	â11.69âkcal	NNP	O
/	/	SYM	O
mol	mol	NN	O
than	than	IN	O
the	the	DT	O
PF-543	PF-543	NNP	O
â9âkcal	â9âkcal	NNP	O
/	/	SYM	O
mol	mol	NN	O
.	.	.	O

The	the	DT	O
MD	MD	NNP	O
simulations	simulation	NNS	O
study	study	NN	O
suggested	suggest	VBD	O
that	that	IN	O
the	the	DT	O
binding	binding	NN	O
of	of	IN	O
ZINC06823429	zinc06823429	CD	O
leads	lead	VBZ	O
to	to	IN	O
unfolding	unfold	VBG	O
of	of	IN	O
SphK1	SphK1	NNP	O
at	at	IN	O
greater	great	JJR	O
extent	extent	NN	O
.	.	.	O

This	this	DT	O
may	may	MD	O
be	be	VB	O
due	due	IN	O
to	to	IN	O
proper	proper	JJ	O
inhibition	inhibition	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
or	or	CC	O
unfolding	unfold	VBG	O
of	of	IN	O
Î±-helical	î±-helical	JJ	O
regions	region	NNS	O
.	.	.	O

The	the	DT	O
trace	trace	NN	O
of	of	IN	O
the	the	DT	O
covariance	covariance	NN	O
matrix	matrix	NN	O
and	and	CC	O
Eigenvalues	Eigenvalues	NNP	O
was	be	VBD	O
higher	high	JJR	O
in	in	IN	O
case	case	NN	O
of	of	IN	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
than	than	IN	O
SphK1âPF-543	SphK1âPF-543	NNP	O
due	due	JJ	O
to	to	IN	O
irregular	irregular	JJ	O
fluctuations	fluctuation	NNS	O
in	in	IN	O
SphK1	SphK1	NNP	O
upon	upon	IN	O
binding	bind	VBG	O
of	of	IN	O
ZINC06823429	ZINC06823429	NNP	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
the	the	DT	O
MMPBSA	MMPBSA	NNP	O
analysis	analysis	NN	O
suggested	suggest	VBD	O
that	that	IN	O
the	the	DT	O
average	average	JJ	O
binding	bind	VBG	O
energy	energy	NN	O
of	of	IN	O
ZINC06823429	ZINC06823429	NNP	O
with	with	IN	O
SphK1	SphK1	NNP	O
was	be	VBD	O
highest	high	JJS	O
among	among	IN	O
all	all	PDT	O
the	the	DT	O
inhibitors	inhibitor	NNS	O
.	.	.	O

The	the	DT	O
average	average	JJ	O
binding	bind	VBG	O
energy	energy	NN	O
of	of	IN	O
SphK1âZINC06823429	SphK1âZINC06823429	NNP	O
and	and	CC	O
SphK1âPF-543	SphK1âPF-543	NNP	O
was	be	VBD	O
found	find	VBN	O
to	to	TO	O
be	be	VB	O
â380âkJ	â380âkj	ADD	O
/	/	SYM	O
mol	mol	NN	O
and	and	CC	O
â276âkJ	â276âkJ	NNP	O
/	/	SYM	O
mol	mol	NN	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

Thus	thus	RB	O
,	,	,	O
to	to	IN	O
the	the	DT	O
best	good	JJS	O
of	of	IN	O
our	-PRON-	PRP$	O
knowledge	knowledge	NN	O
,	,	,	O
this	this	DT	O
is	be	VBZ	O
the	the	DT	O
first	first	JJ	O
computational	computational	JJ	O
predictions	prediction	NNS	O
based	base	VBN	O
on	on	IN	O
LBVS	LBVS	NNP	O
,	,	,	O
molecular	molecular	JJ	O
docking	docking	NN	O
,	,	,	O
MD	MD	NNP	O
simulations	simulation	NNS	O
,	,	,	O
and	and	CC	O
the	the	DT	O
MMPBSA	MMPBSA	NNP	O
calculations	calculation	NNS	O
to	to	TO	O
identify	identify	VB	O
a	a	DT	O
novel	novel	JJ	O
inhibitor	inhibitor	NN	O
that	that	WDT	O
precisely	precisely	RB	O
target	target	VBP	O
SphK1	SphK1	NNP	O
.	.	.	O

Although	although	IN	O
,	,	,	O
we	-PRON-	PRP	O
have	have	VBP	O
performed	perform	VBN	O
detailed	detailed	JJ	O
computational	computational	JJ	O
analysis	analysis	NN	O
of	of	IN	O
drug	drug	NN	O
binding	bind	VBG	O
to	to	IN	O
SphK1	SphK1	NNP	O
,	,	,	O
there	there	EX	O
are	be	VBP	O
many	many	JJ	O
possible	possible	JJ	O
research	research	NN	O
limitations	limitation	NNS	O
.	.	.	O

There	there	EX	O
are	be	VBP	O
no	no	DT	O
experimental	experimental	JJ	O
validations	validation	NNS	O
to	to	TO	O
support	support	VB	O
this	this	DT	O
computational	computational	JJ	O
prediction	prediction	NN	O
.	.	.	O

The	the	DT	O
experimental	experimental	JJ	O
validations	validation	NNS	O
of	of	IN	O
the	the	DT	O
present	present	JJ	O
work	work	NN	O
are	be	VBP	O
needed	need	VBN	O
to	to	TO	O
support	support	VB	O
these	these	DT	O
data	datum	NNS	O
in	in	IN	O
order	order	NN	O
to	to	TO	O
perform	perform	VB	O
proper	proper	JJ	O
clinical	clinical	JJ	O
trials	trial	NNS	O
of	of	IN	O
identified	identify	VBN	O
drug	drug	NN	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
of	of	IN	O
computational	computational	JJ	O
analysis	analysis	NN	O
can	can	MD	O
have	have	VB	O
several	several	JJ	O
variations	variation	NNS	O
when	when	WRB	O
it	-PRON-	PRP	O
is	be	VBZ	O
executed	execute	VBN	O
by	by	IN	O
different	different	JJ	O
software	software	NN	O
using	use	VBG	O
different	different	JJ	O
force	force	NN	O
fields	field	NNS	O
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
the	the	DT	O
chemical	chemical	NN	O
libraries	library	NNS	O
can	can	MD	O
be	be	VB	O
extended	extend	VBN	O
and	and	CC	O
side	side	JJ	O
chain	chain	NN	O
modifications	modification	NNS	O
of	of	IN	O
current	current	JJ	O
drug	drug	NN	O
are	be	VBP	O
needed	need	VBN	O
for	for	IN	O
better	well	JJR	O
efficacy	efficacy	NN	O
.	.	.	O

There	there	EX	O
are	be	VBP	O
remarkable	remarkable	JJ	O
improvements	improvement	NNS	O
in	in	IN	O
the	the	DT	O
field	field	NN	O
of	of	IN	O
protein	protein	NN	O
dynamics	dynamic	NNS	O
,	,	,	O
still	still	RB	O
the	the	DT	O
validations	validation	NNS	O
of	of	IN	O
simulation	simulation	NN	O
methods	method	NNS	O
and	and	CC	O
broad	broad	JJ	O
range	range	NN	O
of	of	IN	O
experimental	experimental	JJ	O
observations	observation	NNS	O
are	be	VBP	O
required	require	VBN	B
.	.	.	O

Additionally	additionally	RB	O
,	,	,	O
the	the	DT	O
theoretical	theoretical	JJ	O
prediction	prediction	NN	O
may	may	MD	O
have	have	VB	O
several	several	JJ	O
variations	variation	NNS	O
when	when	WRB	O
it	-PRON-	PRP	O
comes	come	VBZ	O
to	to	IN	O
experimental	experimental	JJ	O
level	level	NN	O
such	such	JJ	O
as	as	IN	O
difference	difference	NN	O
in	in	IN	O
binding	bind	VBG	O
affinity	affinity	NN	O
of	of	IN	O
predicted	predict	VBN	O
inhibitors	inhibitor	NNS	O
with	with	IN	O
SphK1	SphK1	NNP	O
.	.	.	O

The	the	DT	O
difference	difference	NN	O
may	may	MD	O
arise	arise	VB	O
due	due	IN	O
to	to	IN	O
large	large	JJ	O
number	number	NN	O
of	of	IN	O
possible	possible	JJ	O
poses	pose	NNS	O
of	of	IN	O
an	an	DT	O
inhibitor	inhibitor	NN	O
and	and	CC	O
different	different	JJ	O
folded	fold	VBN	O
conformations	conformation	NNS	O
of	of	IN	O
receptor	receptor	NN	B
.	.	.	O

The	the	DT	O
recent	recent	JJ	O
computational	computational	JJ	O
approaches	approach	NNS	O
were	be	VBD	O
employed	employ	VBN	O
to	to	TO	O
study	study	VB	O
and	and	CC	O
discover	discover	VB	O
new	new	JJ	O
SphK1	SphK1	NNP	O
inhibitors	inhibitor	NNS	O
that	that	WDT	O
could	could	MD	O
be	be	VB	O
a	a	DT	O
starting	starting	NN	O
point	point	NN	O
for	for	IN	O
a	a	DT	O
promising	promising	JJ	O
drug	drug	NN	O
candidate	candidate	NN	O
in	in	IN	O
the	the	DT	O
treatment	treatment	NN	O
of	of	IN	O
breast	breast	NN	O
cancer	cancer	NN	O
.	.	.	O

Various	various	JJ	O
repositories	repository	NNS	O
of	of	IN	O
chemical	chemical	JJ	O
compounds	compound	NNS	O
such	such	JJ	O
as	as	IN	O
DrugBank	DrugBank	NNP	O
,	,	,	O
Ligand	Ligand	NNP	O
Expo	Expo	NNP	O
,	,	,	O
ChEMBL	ChEMBL	NNP	O
,	,	,	O
ChEBI	ChEBI	NNP	O
,	,	,	O
GLASS	GLASS	NNP	O
,	,	,	O
HMDB	HMDB	NNP	O
,	,	,	O
and	and	CC	O
ZINC	ZINC	NNP	O
databases	database	NNS	O
were	be	VBD	O
used	use	VBN	O
to	to	TO	O
perform	perform	VB	O
LBVS	LBVS	NNP	O
.	.	.	O

The	the	DT	O
screened	screen	VBN	O
compounds	compound	NNS	O
along	along	IN	O
with	with	IN	O
standard	standard	JJ	O
PF-543	PF-543	NNP	O
have	have	VBP	O
been	be	VBN	O
taken	take	VBN	O
forward	forward	RB	O
to	to	TO	O
evaluate	evaluate	VB	O
drug	drug	NN	O
likeness	likeness	NN	O
,	,	,	O
ADMET	admet	JJ	O
properties	property	NNS	O
,	,	,	O
lead	lead	VBP	O
likeness	likeness	NN	O
,	,	,	O
and	and	CC	O
PAINS	PAINS	NNP	O
analyses	analysis	NNS	O
.	.	.	O

Further	further	RB	O
,	,	,	O
docking	docking	NN	O
study	study	NN	O
revealed	reveal	VBD	O
that	that	IN	O
the	the	DT	O
ligand	ligand	NN	O
ZINC06823429	ZINC06823429	NNP	O
has	have	VBZ	O
greater	great	JJR	O
binding	bind	VBG	O
energy	energy	NN	O
â11.36âkcal	â11.36âkcal	JJ	O
/	/	SYM	O
mol	mol	NN	O
than	than	IN	O
PF-543	PF-543	NNP	O
â9.90âkcal	â9.90âkcal	NNP	O
/	/	SYM	O
mol	mol	NN	O
.	.	.	O

It	-PRON-	PRP	O
was	be	VBD	O
subsequently	subsequently	RB	O
strengthened	strengthen	VBN	O
by	by	IN	O
MD	MD	NNP	O
simulation	simulation	NN	O
and	and	CC	O
MMPBSA	MMPBSA	NNP	O
calculations	calculation	NNS	O
to	to	TO	O
check	check	VB	O
the	the	DT	O
stability	stability	NN	O
of	of	IN	O
its	-PRON-	PRP$	O
mode	mode	NN	O
of	of	IN	O
binding	bind	VBG	O
and	and	CC	O
thereby	thereby	RB	O
inhibiting	inhibit	VBG	O
activity	activity	NN	O
of	of	IN	O
SphK1	SphK1	NNP	O
.	.	.	O

The	the	DT	O
present	present	JJ	O
study	study	NN	O
predicted	predict	VBD	O
strong	strong	JJ	O
inhibitory	inhibitory	JJ	O
effects	effect	NNS	O
of	of	IN	O
new	new	JJ	O
compound	compound	NN	O
that	that	WDT	O
could	could	MD	O
become	become	VB	O
a	a	DT	O
starting	starting	NN	O
point	point	NN	O
for	for	IN	O
future	future	JJ	O
development	development	NN	O
and	and	CC	O
structure	structure	NN	O
activity	activity	NN	O
relationship	relationship	NN	O
studies	study	NNS	O
for	for	IN	O
the	the	DT	O
discovery	discovery	NN	O
of	of	IN	O
new	new	JJ	O
SphK1	SphK1	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

The	the	DT	O
experimental	experimental	JJ	O
validations	validation	NNS	O
are	be	VBP	O
further	further	RB	O
required	require	VBN	O
to	to	TO	O
support	support	VB	O
this	this	DT	O
outcome	outcome	NN	O
in	in	IN	O
order	order	NN	O
to	to	TO	O
perform	perform	VB	O
proper	proper	JJ	O
clinical	clinical	JJ	O
trials	trial	NNS	O
.	.	.	O

The	the	DT	O
computational	computational	JJ	O
prediction	prediction	NN	O
may	may	MD	O
have	have	VB	O
different	different	JJ	O
inhibitory	inhibitory	JJ	O
effects	effect	NNS	O
and	and	CC	O
binding	bind	VBG	O
affinity	affinity	NN	O
of	of	IN	O
inhibitor	inhibitor	NN	O
with	with	IN	O
SphK1	SphK1	NNP	O
.	.	.	O

The	the	DT	O
difference	difference	NN	O
may	may	MD	O
arise	arise	VB	O
due	due	IN	O
to	to	IN	O
large	large	JJ	O
number	number	NN	O
of	of	IN	O
possible	possible	JJ	O
poses	pose	NNS	O
of	of	IN	O
an	an	DT	O
inhibitor	inhibitor	NN	O
and	and	CC	O
different	different	JJ	O
folded	fold	VBN	O
conformations	conformation	NNS	O
of	of	IN	O
receptor	receptor	NN	O
.	.	.	O

